USP30 inhibitor compounds and their use in treating medical conditions

Isoquinolinone compounds inhibit USP30 to enhance mitophagy, addressing mitochondrial dysfunction in a range of disorders including Parkinson's disease and kidney diseases, offering therapeutic benefits across multiple age-related conditions.

WO2026236220A1PCT designated stage Publication Date: 2026-11-12VINCERE BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026699
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for USP30-mediated disorders, such as Parkinson's disease, Alzheimer's disease, kidney diseases, heart failure, pulmonary fibrosis, Duchenne Muscular Dystrophy, and cancer, lack effective therapeutic methods to address mitochondrial dysfunction and mitophagy deficits.

Method used

Development of isoquinolinone and related compounds that inhibit USP30 protein activity, enhancing mitophagy and improving mitochondrial quality control.

Benefits of technology

The compounds enhance mitophagy, potentially slowing or stopping neurodegeneration in Parkinson's disease, reducing oxidative damage in kidney diseases, improving cardiac function, and offering therapeutic benefits in various age-related disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000011_0001
    Figure IMGF000011_0001
Patent Text Reader

Abstract

The invention provides isoquinolinone and related compounds, pharmaceutical compositions, and their use in treating Parkinson's disease and other disorders.
Need to check novelty before this filing date? Find Prior Art

Description

USP30 INHIBITOR COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 799,935, filed on May 5, 2025, the entirety of which is hereby incorporated by reference.FIELD OF THE INVENTION

[0002] The invention provides isoquinolinone and related compounds, pharmaceutical compositions, and their use in treating Parkinson’s disease and other disorders.BACKGROUND

[0003] USP30 is a deubiquitinating enzyme (DUB) that is primarily present on the mitochondrial outer membrane and peroxisomal membrane. As the sole DUB on the mitochondrial outer membrane, it can counteract the actions of several E3 ligases that ubiquitinate outer mitochondrial membrane proteins, including but not limited to, parkin, march5, and mull. Through this post-translational modification, USP30 can dynamically alter several mitochondrial quality control mechanisms including but not limited to mitophagy and fusion with other mitochondria. Reduction of USP30 through knockout or knockdown can increase basal and stress-induced mitophagy (Bingol et al., 2014, PMID: 24896179; Fang et al., 2023 PMID: 37957154). Mitophagy is the process through which damaged mitochondria are removed through selective autophagy. This process is generally initiated when the kinase pinkl accumulates on damaged mitochondria (where it would ordinarily be imported and cleaved by healthy mitochondria). Pinkl phosphorylates ubiquitin chains on the outer mitochondrial membrane, which recruits and partially activates the E3 ligase parkin from the cytosol. Parkin is then fully activated through phosphorylation by pinkl and, upon this activation, rapidly ubiquitinates outer mitochondrial membrane proteins such as MFNs, which then recruit autophagy receptors and initiate the engulfing of the mitochondria by the autophagosome and eventual degradation by lysosomes. In this way, USP30 acts both upstream of pinkl / parkin by reducing the number of ubiquitins that can be phosphorylated by pinkl and downstream of parkin by removing ubiquitin chains added by the E3 ligase.1168195189143870-5007-WO

[0004] The process of mitophagy is reduced with age, in part mediated by reductions in levels of soluble parkin and expression of pinkl with age. This may have a direct impact on aging since increasing expression of parkin increases lifespan and healthspan in fruit flies (Rana et al., PMID: 23650379). For this reason, the mitophagy pathway may be key to both diseases that directly affect mitochondria, and those that have an aging component.

[0005] One age-related disease that is directly affected by mitophagy deficits is Parkinson’s disease (PD). Genetic mutations in 6 genes that are involved in the mitophagy pathway cause early onset forms of PD and directly establish a cause-and-effect relationship to the disease. Specifically, genetic studies of monogenic PD show that pathogenic mutations in genes encoding proteins participating in mitochondrial quality control, such as PINK1, PRKN, FBXO7, DJ-l, VPS13C, and CHCHD2, cause autosomal recessive, early-onset parkinsonism (Canet-Aviles et al., 2004, PMID: 15181200; Funayama etal., 2015, PMID: 25662902; Burchell etal., 2013, PMID: 23933751; Lesage etal., 2016, PMID: 26942284; Paisan-Ruiz etal., 2010, PMID:20669327).

[0006] Importantly, Genome-Wide Association (GW A) studies of sporadic PD show that mitochondrial-function-associated genes are also risk factors for sporadic, late-onset PD (Billingsley et al., 2019, PMID: 31123700). Moreover, a decrease in respiratory capacity of mitochondria has been shown in autopsied brain tissue from sporadic PD cases (Schapira et al., 1990, PMID: 2154550). Recent evidence from peripheral blood cells of early / prodromal PD cases also demonstrates mitochondrial dysfunction (Smith etal., 2018, PMID: 30294923).Finally, mitochondrial complex 1 inhibitors, such as MPTP or Rotenone, cause retrograde degeneration of nigrostriatal dopamine neurons in humans and animals highlighting that these neurons with the most severe and prototypical degeneration in PD are particularly sensitive to mitochondrial dysfunction. Modulating mitochondrial pathways, including increasing expression of Parkin or depletion of USP30, has been shown to be protective in a variety of genetic and toxin-based animal models of PD in multiple species (Bingol et al., 2014, PMID: 24896179; Bian e / a / ., 2012, PMID: 22792139; Hou etal., 2015, PMID: 26364802; Lo Bianco et al., 2004, PMID: 15576511; Paterna et al., 2007, PMID: 17299411; Vercammen et al., 2006, PMID: 16914382; Yasuda et al., 2011, PMID: 21760537; Yasuda etal., 2007, PMID: 17101231; Liang et al., 2015, PMID: 25739811). Enhancing mitophagy therefore has potential to slow or stop the progressive neurodegeneration and accompanying symptoms in PD.2168195189 143870-5007-WO

[0007] Abnormal mitochondrial accumulation and mitophagy deficits have been observed in other age-related diseases such as Alzheimer’s disease (AD) and with aging itself (Fang et al., 2019, PMID: 30742114; Ridge and Kauwe, 2018, PMID: 29564191). Recent work by Fang et al. demonstrates that mitophagy is reduced in the hippocampus of AD patients, and increased mitophagy is able to rescue cognitive impairment and prevent both A plaques and tau hyperphosphorylation in induced pluripotent stem cells (iPSC) and multiple animal models of AD (Fang et al., 2019, PMID: 30742114). Positron Emission Tomography (PET) imaging of AD patients has suggested reduced oxidative phosphorylation and TCA cycle, while postmortem analysis suggests a reduction in PGCla, a transcriptional regulator of mitochondrial biogenesis and an essential part of the mitochondrial quality control cycle (Kapogiannis and Mattson, 2011, PMID: 21147038; Katsouri etal., 2016, PMID: 27791018). Transmission Electron Microscopy (TEM) analysis of mitochondrial structures in the hippocampus of postmortem AD patients demonstrates abnormal mitochondrial morphology, altered mitophagy, and a reduction in parkin levels, which were exacerbated with disease progression (Ye et al., 2015, PMID: 25678552).

[0008] Inhibition of USP30 may also provide benefit in diseases that affect the kidney, including but not limited to, acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease (DKD), Polycystic Kidney Disease (PKD), igA Nephropathy (igAN), and others. There have been several in vivo studies showing that mitophagy plays an important role in protecting from renal insult following AKI in various specific kidney injury models (Liu et al., 2021, PMID: 33602903). Specifically, mitophagy has been shown to attenuate the damage caused by IRI (Livingston etal., 2019, PMID: 31066324; Tang etal., 2018, PMID: 31703649; van der Vorst et al., 2019, PMID: 31646922), decreasing the chance that it develops into CKD. Nephrotoxic substances can also result in AKI. Cisplatin is currently used as chemotherapy for a wide range of cancers, but a major side effect is nephrotoxicity. Cisplatin has been shown to induce AKI in a dose-dependent manner. AKI was reported in 69% of head and neck cancer patients treated with high dose of cisplatin (n=124) (Duan et al., 2020, PMID: 32489432). Other studies have also reported a high incidence of AKI after cisplatin treatment, nephrotoxicity being the limiting factor of the chemotherapy regimen (Hoek et al., 2016, PMID: 26891330; Zhao et al., 2017, PMID: 28024839). Previous work has demonstrated that inducing mitophagy can reduce nephrotoxicity, suggesting that mitophagy enhancers may be a good option to combine3168195189 143870-5007-WOwith cisplatin as a chemotherapy regimen (Hamdi et al., 2012, PMID: 22583774). Human data also points at the role of impaired mitophagy in renal injury (Su et al., 2022, PMID: 35678504). Impairment of mitophagy activation was observed in CKD patients (Akposso et al., 2000, PMID: 10872131). The expression of PGC-la (regulator of mitochondrial biogenesis) was decreased in kidneys from CKD patients (Su et al., 2022, PMID: 35678504), and this decrease correlated with the glomerular filtration rate and with fibrosis (Yang et al., 2010, PMID: 21286234). In diabetic kidney disease (DKD), kidney biopsies pointed at suppression of mitochondrial activity, lower gene expression of PGCla (Shigeoka et al., 2010, PMID: 20962258), and mitochondrial fragmentation (Jin et al., 2022, PMID: 35524750; Chen etal., 2013, PMID: 24474954). Human studies also found that mitochondrial oxidative stress in CKD kidneys was higher than in healthy kidneys. In igAN, elevated mitochondrial DNA has been observed in both urine and blood of patients, and mtDNA is a consistent biomarker of the disease suggesting the presence of mitochondrial abnormalities (Yu et al., 2019, PMID: 31690796; Liu et al., 2023, PMID:36880600). Taken together, these data suggest that mitochondria become highly damaged in AKI, further contributing to oxidative damage and cell death, and that clearing these damaged mitochondria through inhibition of USP30 may be beneficial in renal diseases.

[0009] The heart contains the highest mitochondrial content of any tissue, making it the most metabolically active organ in the body, with mitochondria comprising -30% of cell volume in mammalian species (Brown etal., 2017, PMID: 28004807). Accumulation of dysfunctional mitochondria is also a major contributor to aging, and aging remains the biggest risk factor for heart failure (HF). With cardiac aging, mitochondria become enlarged and dysfunctional, with increase in reactive oxygen species (ROS) production and decrease in calcium homeostasis leading to senescent cardiomyocytes (Song et al., 2018, PMID: 30421395). These senescent cells lose the ability to divide and begin to release Senescence- Associated Secretory Phenotype (SASP) that leads to tissue-level decline (Bratic and Larsson, 2013, PMID: 23454757; Kim, 2019, PMID: 30907989). Mitochondrial maintenance, including mitophagy, is essential for cardiac homeostasis. Mitophagy is a selective form of autophagy wherein cells eliminate damaged or dysfunctional mitochondria through a ubiquitin-regulated process. Dysregulation of mitophagy causes accumulation of dysfunctional mitochondria, loss of myocytes, and contractile dysfunction (Billia etal., 2011, PMID 21606348; Hoshino etal., 2013, PMID 23917356; Kubli etal., 2013, PMID 23986804; Shires and Gustafsson, 2015, PMID 25609139). Loss of parkin, a4168195189 143870-5007-WOdriver of mitophagy, leads to accumulation of damaged mitochondria in myocytes, development of HF, and increased mortality after myocardial infarction in mice (Shires and Gustafsson, 2015, PMID 25609139). Conversely, increasing mitophagy prevents cellular senescence in aging models of mice and rats (Hoshino et al., 2013, PMID 23917356; Cebe et al., 2014, PMID 25384832; Li et al., 2021, PMID 34035486; Lu et al., 2006, PMID 16707173). Taken together, data suggest that increasing mitophagy has the potential to both act as a preventative or therapeutic for cardiac aging and reduce damage following cardiac injury such as but not limited to myocardial infarction.

[0010] Patients with idiopathic pulmonary fibrosis (LPF) have a greatly elevated percentage of abnormal mitochondria in alveolar type II cells, which are not replaced by new mitochondria as they should be. Convergent evidence — specifically, human pharmacology, genetics, and tissue pathology as well as animal model data — indicate that restoration of bioenergetics and mitochondrial quality control hold great promise for treating IPF (Kobayashi et al., 2016, PMID 27279371; Bueno etal., 2019, PMID 31170232).

[0011] Numerous studies indicate that mitochondrial dysfunction is both an early hallmark of Duchenne Muscular Dystrophy (DMD) and contributes to its progression (Brouilly et al., 2015, PMID 26358775; Kuznetsov etal., 1998, PMID 9655182; Scholte etal., 1985, PMID 4022395; Sperl etal., 1997, PMID 9309668; Vila eta / ., 2017, PMID 27834955). Support for this includes the high numbers of large, damaged mitochondria in the muscle, decreased mitophagy related genes, and increased reactive oxygen species (ROS) levels. Additionally, DMD muscles exhibit reduced mitochondrial respiration and nicotinamide NAD+ mediated mitochondrial biogenesis, altered organelle localization, and enlarged mitochondria with reduced membrane potential. These data suggest that mitochondrial dysfunction may be due to a combination of decreased new mitochondria production and a buildup of damaged mitochondria not properly removed by mitophagy.

[0012] As mitochondria are key to cellular and organismal health, the potential benefits of mitophagy enhancement extend far beyond the above indications including emerging evidence of involvement in the formation and proliferation of cancerous tissue. In a recent (2021) study, it was demonstrated that USP30 is upregulated in human hepatocellular carcinoma (HCC) tumor compared to neighboring normal tissue, and knockout of USP30 in mice largely attenuated5168195189 143870-5007-WOhepatocarcinogenesis and inflammation in the DEN-induced HCC model in a manner that was uninfluenced by high-fat diet (Gu et al., 2021, PMID: 32221968).

[0013] Accordingly, the need exists for new therapeutic methods and compounds for treating USP30-mediated disorders, diseases, or conditions, such as Parkinson’s disease. The present invention addresses the foregoing needs and provides other related advantages.SUMMARY

[0014] The invention provides isoquinolinone and related compounds, pharmaceutical compositions, and their use in treating Parkinson’s disease and other disorders. In particular, one aspect of the invention provides a collection of isoquinolinone and related compounds, such as a compound represented by Formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of isoquinolinone and related compounds are described in the detailed description. The compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

[0015] Another aspect of the invention provides a method of treating a USP30-mediated disorder, disease, or condition in a patient. The method comprises administering to said patient in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I, as further described in the detailed description.

[0016] Another aspect of the invention provides a method of inhibiting a USP30 protein. The method comprises contacting a USP30 protein with an effective amount of a compound described herein, such as a compound of Formula I, to thereby inhibit the USP30 protein, as further described in the detailed description.6168195189 143870-5007-WODETAILED DESCRIPTION

[0017] The invention provides isoquinolinone and related compounds, pharmaceutical compositions, and their use in treating Parkinson’s disease and other disorders. The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in Comprehensive Organic Synthesis (B. M. Trost & I. Fleming, eds., 1991-1992); Handbook of Experimental Immunology (D. M. Weir & C. C. Blackwell, eds.); Current Protocols in Molecular Biology" (F. M. Ausubel et al., eds., 1987, and periodic updates); and Current Protocols in Immunology (J. E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety.

[0018] Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls.Definitions

[0019] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “-O-alkyl” etc. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0020] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely7168195189 143870-5007-WOsaturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0021] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as wz / v -fused or spirocyclic. As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom.8168195189 143870-5007-WOUnless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:

[0023] The term “lower alkyl” refers to a Ci-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0024] The term “lower haloalkyl” refers to a Ci-4 straight or branched alkyl group that is substituted with one or more halogen atoms.9168195189 143870-5007-WO

[0025] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2 / f-pyrrolyl), NH (as in pyrrolidinyl) or NR (as in N-substituted pyrrolidinyl)).

[0026] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.

[0027] As used herein, the term “bivalent Ci-s (or Ci-s) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0028] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, z.t?., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0029] The term “-(Co alkylene)-“ refers to a bond. Accordingly, the term “-(C0-3 alkylene)-” encompasses a bond (i.e., Co) and a -(C1-3 alkylene)- group.

[0030] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group. The term “fluoroalkylene” refers to an alkenylene group that is substituted with at least one fluoro group.

[0031] The terms “halogen” and “halo” mean F, Cl, Br, or I.

[0032] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The10168195189 143870-5007-WOterm “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl groupwhen it has two groups attached to it (e.g.,“phenylene” is a trivalent phenyl groupwhen it has three groups attached t. Theterm “arylene” refers to a bivalent aryl group. The term “naphthalenylene” refers to a multivalent naphthalenyl group having the appropriate number of open valences to account for groups attached to it.

[0033] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 z electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0034] The term “heteroarylene” refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it. For example, “heteroarylene” is a11168195189 143870-5007-WObivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it. The term “pyridinylene” refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it. For example, “pyridinylene” is a bivalent pyridine radical when it has two groupsattached to it (e.g.,“pyridinylene” is a trivalent pyridine radical when it has threegroups attached t

[0035] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms independently selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-27f-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in / V substituted pyrrolidinyl).

[0036] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6-azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 37 / indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl”12168195189 143870-5007-WOrefers to a heterocyclyl substituted by one or more oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it. The term “oxo-heterocyclylene” refers to a multivalent oxo-heterocyclyl group having the appropriate number of open valences to account for groups attached to it.

[0037] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0038] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0039] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from halogen; -(CH2)o-4R°; -(CH2)o-40R°; -0(CH2)o-4R°, -0-(CH2)o-4C(O)OR°; -(CH2)O 4CH(OR°)2; -(CH2)o 4SR0; -(CH2)o 4PI1, which may be substituted with R°; -(CH2)o 40(CH2)o iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o 40(CH2)o 1 -pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)O 4N(RO)2; -(CH2)O 4N(RO)C(O)R°; -N(R°)C(S)R°; -(CH2)O 4N(RO)C(O)NR°2;-N(RO)C(S)NR°2; -(CH2)O^N(R°)C(0)OR°; -N(R°)N(R°)C(O)R°; -N(R°)N(RO)C(0)NRO2; -N(R°)N(R°)C(O)OR°; -(CH2)o4C(O)R°; -C(S)R°; -(CH2)o- ^C(O)OR°; -(CH2)o4C(O)SR°; -(CH2)O KXOjOSiRA; -(CH2)o4OC(O)R°; -OC(0)(CH2)O-ISR-, SC(S)SR°; -(CH2)o4SC(O)R°;13168195189 143870-5007-WO-(CH2)O-4C(0)NR°2; -C(S)NRO2; -C(S)SR°; -SC(S)SR°, -(CH2)O 4OC(O NRO2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)o4SSR°; -(CH2)04S(O)2R°; -(CH2O4S(O2ORO; -(CH2)O 4OS(O)2RO; -S(O)2NRO2; -S(O)(NR°)R°; -S(O)2N=C(NRO2)2; -(CH2)O4S(0)RO; -N(R°)S(0)2NRO2; -N(R°)S(0)2RO; -N(OR°)R°; -C(NH)NR°2; -P(O)2RO; -P(O)RO2; -OP(O)RO2; -OP(O)(ORO)2; SiR°3; -(Ci^ straight or branched alkylene)O-N(R°)2; or -(Ci-4 straight or branched alkylene)C(O)O-N(R°)2.

[0040] Each R° is independently hydrogen, Ci-6 aliphatic, -CH2Ph, -0(CH2)o-iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono-or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted by a divalent substituent on a saturated carbon atom of R° selected from =0 and =S; or each R° is optionally substituted with a monovalent substituent independently selected from halogen, -(CH2)Q_2R*, -(haloR*), -(CH2)o2OH, -(CH2)o2OR*, -(CH2)0 2CH(OR*)2; -O(haloR’), -CN, -N3, -(CH2)0 2C(O)R*, -(CH2)o2C(O)OH, -(CH2)02C(O)OR*, -(CH2)O 2SR*, -(CH2)O 2SH, -(CH2)O 2NH2, -(CH2)O 2NHR*, -(CH2)O 2NR’2, -NO2, -SiR*3, -OSiR*3, -C(O)SR* -(Ci-4straight or branched alkylene)C(O)OR*, or -SSR*.

[0041] Each R* is independently selected from Ci-4 aliphatic, -CH2Ph, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens; or wherein an optional substituent on a saturated carbon is a divalent substituent independently selected from =0, =S, =NNR =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR\ =N0R*, -O(C(R*2))2 3O-, or-S(C(R*2))2-3S-, or a divalent substituent bound to vicinal substitutable carbons of an “optionally substituted” group is -O(CR*2)2 3O-, wherein each independent occurrence of R is selected from hydrogen, Ci-6 aliphatic or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0042] When R* is Ci-6 aliphatic, R* is optionally substituted with halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or 14168195189 143870-5007-WO-N02, wherein each R* is independently selected from C1-4 aliphatic, -CH2Ph, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens.

[0043] An optional substituent on a substitutable nitrogen is independently -R^, -NR ^2, -C(O)Rf, -C(O)ORf, -C(O)C(O)Rt, -C(O)CH2C(O)Rt, -S(O)2R+, -S(O)2NRt2, -C(S)NRt2, -C(NH)NRt2, or -N(Rt)S(O)2Rt; wherein each Rtis independently hydrogen, C1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R+, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when R' is C1-6 aliphatic, R' is optionally substituted with halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is independently selected from C1-4 aliphatic, -CH2Ph, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R* is unsubstituted or where preceded by halo is substituted only with one or more halogens.

[0044] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1—19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate,15168195189 143870-5007-WObenzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0045] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D. C. on their website). These disclosures are incorporated herein by reference.

[0046] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N (Ci 4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0047] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. The invention includes compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by16168195189 143870-5007-WOdeuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.

[0048] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g, hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.

[0049] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. Further, to the extent a compound described herein may exist as an atropisomer (e.g, substituted biaryls), all forms of such atropisomer are considered part of this invention.

[0050] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0051] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.17168195189 143870-5007-WO

[0052] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and Ci-Ce alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3-methyl-l -pentyl, 4-m ethyl- 1 -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.

[0053] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein,.g, as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group.

[0054] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.

[0055] The term “hydroxyalkyl” refers to an alkyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH2C(H)(OH)CH2CH2OH, and the like.

[0056] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

[0057] The terms “alkoxyl” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, / c / 7-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like

[0058] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane substituted with an oxo group is cyclopentanone.18168195189 143870-5007-WO

[0059] The symbol “ ” indicates a point of attachment.

[0060] When a chemical structure containing a ring is depicted with a substituent having a bond that crosses a ring bond, the substituent may be attached at any available position on thering. For example, the chemical structureand. In the context of a polycyclic fused ring, when a chemical structure containing a polycyclic fused ring is depicted with one or more substituent(s) having a bond that crosses multiple rings, the one or more substituent(s) may be independently attached to any of the ringscrossed by the bond. To illustrate, the chemical structurefor example,

[0061] When any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0062] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.19168195189 143870-5007-WO

[0063] As used herein, the terms “subject” and “patient” are used interchangeable and refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans.

[0064] The term “IC50” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target.

[0065] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g, a therapeutic, ameliorative, inhibitory or preventative result). An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.

[0066] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0067] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA

[1975] ,

[0068] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0069] In addition, when a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed. Such acidic and basic salts used20168195189 143870-5007-WOwithin the scope of the invention are pharmaceutically acceptable ( / .e., non-toxic, physiologically acceptable) salts. Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0070] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0071] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.I. Isoquinolinone and Related Compounds

[0072] One aspect of the invention provides isoquinolinone and related compounds. The compounds may be used in the pharmaceutical compositions and therapeutic methods described herein. Exemplary compounds are described in the following sections, along with exemplary procedures for making the compounds.

[0073] One aspect of the invention provides a compound represented by Formula I:or a pharmaceutically acceptable salt thereof; wherein:R1and R9are independently hydrogen or C1-4 alkyl;R2is phenyl; a 5-6 membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 4-7 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 4-7 membered deuteroheterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen,21168195189 143870-5007-WOoxygen, and sulfur; C1.5 alkyl; C3-7 cycloalkyl; Ci.4haloalkyl; C2-4 alkenyl; C2-C4 allenyl; or C2-4alkynyl; wherein the phenyl, heteroaryl, cycloalkyl, heterocyclyl, deuteroheterocyclyl, C2-4 alkenyl, and C2-4alkynyl are substituted by m occurrences of R4;R3is -S(O)2N(R5)(R6);R4represents independently for each occurrence C1-4 alkyl, Ci.4haloalkyl, halo, C3-7 cycloalkyl, hydroxyl, cyano, or Ci-4alkoxyl;R5is hydrogen or C1-6 alkyl;R6is C1-6 hydroxyalkyl, -(C0-4 alkylene)-(C3-7 cycloalkyl substituted by hydroxyl), -(Co-4 alkylene)-(C3-7 cycloalkyl substituted by -N(R12)(R13)), -(C3-7cycloalkylene)-(Ci-6 hydroxyalkyl), -(Co-4alkylene)-N(R12)(R13), -(Co-4alkylene)-(3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R11), or -(Co-4alkylene)-(5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R11);R7and R8each represent independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or C3-7 cycloalkyl;R10is C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, or C3-7 cycloalkyl;R11represents independently for each occurrence C1-4 alkyl, C 1-4 haloalkyl, halo, C3-7 cycloalkyl, hydroxyl, or Ci-4alkoxyl;R12and R13are independently hydrogen, Ci-6 alkyl, or C3-7 cycloalkyl;A2is phenylene, pyridinylene, or naphthalenylene, each of which is substituted with q occurrences of R8;L1is -C(O)N(R9)-;X is C1-5 alkylene;m is 0, 1, 2, or 3; andn, t, and q are independently 0, 1, or 2.

[0074] The definitions of variables in Formula I above encompass multiple chemical groups. The application contemplates embodiments where, for example, (i) the definition of a variable is22168195189 143870-5007-WOa single chemical group selected from those chemical groups set forth above, (ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and (iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0075] In certain embodiments, the compound is a compound of Formula I.

[0076] As defined generally above, R1and R9are independently hydrogen or Ci-4 alkyl. In certain embodiments, R1is hydrogen. In certain embodiments, R1is Ci-4 alkyl. In certain embodiments, R9is hydrogen. In certain embodiments, R9is Ci-4 alkyl. In certain embodiments, R1is selected from the groups depicted in the compounds in Table 1 below. In certain embodiments, R9is selected from the groups depicted in the compounds in Table 1 below.

[0077] As defined generally above, R2is phenyl; a 5-6 membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 4-7 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 4-7 membered deuteroheterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; C1-5 alkyl; C3-7 cycloalkyl; Ci-4haloalkyl; C2-4 alkenyl; C2-C4 allenyl; or C2-4alkynyl; wherein the phenyl, heteroaryl, cycloalkyl, heterocyclyl, deuteroheterocyclyl, C2-4 alkenyl, and C2-4alkynyl are substituted by m occurrences of R4. In certain embodiments, R2is phenyl substituted by m occurrences of R4. In certain embodiments, R2is a 5-6 membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted by m occurrences of R4. In certain embodiments, R2is a 4-7 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted by m occurrences of R4. In certain embodiments, R2is C1-3 alkyl or C2-4alkynyl. In certain embodiments, R2is a 4-7 membered deuteroheterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the deuteroheterocyclyl is substituted by m occurrences of R4. In certain embodiments, R2is C1.5 alkyl. In certain embodiments, R2is Ci-4haloalkyl. In certain embodiments, R2is -CF3. In certain embodiments, R2is C2-4 alkenyl. In certain embodiments, R2is C2-C4 allenyl. In certain embodiments, R2is C2-4 alkynyl. In certain embodiments, R2is a 5-6 membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heterocyclyl23168195189 143870-5007-WOcontaining 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the heteroaryl and heterocyclyl are substituted by m occurrences of R4. In certain embodiments, R2is C3-7 cycloalkyl. In certain embodiments, R2is C4-6 cycloalkyl substituted by m occurrences of R4. In certain embodiments, R2is selected from the groups depicted in the compounds in Table 1 below.

[0078] As defined generally above, R3is -S(O)2N(R5)(R6). In certain embodiments, R3is -S(O)2N(R5)(R6). In certain embodiments, R3is selected from the groups depicted in the compounds in Table 1 below.

[0079] As defined generally above, R4represents independently for each occurrence C1-4 alkyl, Ci-4haloalkyl, halo, C3-7 cycloalkyl, hydroxyl, cyano, or Ci-4alkoxyl. In certain embodiments, R4is C1-4 alkyl. In certain embodiments, R4is Ci-4haloalkyl. In certain embodiments, R4is halo. In certain embodiments, R4is C3-7 cycloalkyl. In certain embodiments, R4is hydroxyl. In certain embodiments, R4is cyano. In certain embodiments, R4is C alkoxyl. In certain embodiments, R4is selected from the groups depicted in the compounds in Table 1 below.

[0080] As defined generally above, R5is hydrogen or Ci-6 alkyl. In certain embodiments, R5is hydrogen. In certain embodiments, R5is C1-6 alkyl. In certain embodiments, R5is selected from the groups depicted in the compounds in Table 1 below.

[0081] As defined generally above, R6is Ci-6 hydroxyalkyl, -(Co-4 al kylene)-(C3-7 cycloalkyl substituted by hydroxyl), -(C0-4 alkylene)-(C3-7 cycloalkyl substituted by -N(R12)(R13)), -(C3-7 cycloalkylene)-(Ci-6 hydroxyalkyl), -(Co-4alkylene)-N(R12)(R13), -(Co-4alkylene)-(3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R11), or -(Co-4alkylene)-(5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R11).

[0082] In certain embodiments, R6is Ci-6 hydroxyalkyl, -(C0-4 alkylene)-(C3-7 cycloalkyl substituted by hydroxyl), or -(C3-7 cycloalkylene)-(Ci-6 hydroxy alkyl). In certain embodiments, R6is -(Co-4alkylene)-(3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R11) or -(Co-4alkylene)-(5-6 membered heteroaryl containing 1, 2, or 324168195189 143870-5007-WOheteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R11).

[0083] In certain embodiments, R6is Ci-6 hydroxyalkyl. In certain embodiments, R6is -(Co-4 alkylene)-(C3-7 cycloalkyl substituted by hydroxyl). In certain embodiments, R6is -(Co-4 alkylene)-(C3-7 cycloalkyl substituted by -N(R12)(R13)). In certain embodiments, R6is -(C3-7 cycloalkylene)-(Ci-6 hydroxyalkyl). In certain embodiments, R6is -(Co-4alkylene)-N(R12)(R13). In certain embodiments, R6is -(Co-4alkylene)-(3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R11). In certain embodiments, R6is -(Co-4alkylene)-(5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R11).

[0084] In certain embodiments, R6is OH in certain embodiments, R6is °H. Incertain embodiments,. In certain embodiments,in certainembodiments, R6isincertain embodiments, R6is. In certainembodiments, R6isin certain embodiments, R6isincertainembodiments, R6is. In certain embodiments, R6is. In certainembodiments, R6is. In certain embodiments, R6is. Incertain embodiments, R6is. In certain embodiments, R6iscertain embodiments, R6isIn certain embodiments, R6is. In certain25168195189 143870-5007-WOembodiments, R6isIn certain embodiments, R6iscertain embodiments, R6isIn certain embodiments, R6isIn certain embodiments, R6is. In certainembodiments, R6isIn certain embodiments,certainembodiments, R6isIn certain embodiments, R6is. In certain embodiments, R6is selected from the groups depicted in the compounds in Table 1 below.

[0085] As defined generally above, R7and R8each represent independently for each occurrence halo, C1-4 alkyl, Ci.4haloalkyl, or C3-7 cycloalkyl. In certain embodiments, R7is halo. In certain embodiments, R7is fluoro. In certain embodiments, R7is C1.4 alkyl. In certain embodiments, R7is Ci-4haloalkyl. In certain embodiments, R7is C3-7 cycloalkyl. In certain embodiments, R8is halo. In certain embodiments, R8is C1.4 alkyl. In certain embodiments, R8is Ci-4haloalkyl. In certain embodiments, R8is C3-7 cycloalkyl. In certain embodiments, R7is selected from the groups depicted in the compounds in Table 1 below. In certain embodiments, R8is selected from the groups depicted in the compounds in Table 1 below.

[0086] As defined generally above, R10is C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, or C3-7 cycloalkyl. In certain embodiments, R10is C1-6 alkyl. In certain embodiments, R10is C1-6 haloalkyl. In certain embodiments, R10is C1-6 hydroxyalkyl. In certain embodiments, R10is C3-7 cycloalkyl. In certain embodiments, R10is selected from the groups depicted in the compounds in Table 1 below.

[0087] As defined generally above, R11represents independently for each occurrence C1-4 alkyl, Ci-4haloalkyl, halo, C3-7 cycloalkyl, hydroxyl, or Ci-4alkoxyl. In certain embodiments, R11is C1-426168195189 143870-5007-WOalkyl. In certain embodiments, R11is Ci-4haloalkyl. In certain embodiments, R11is halo. In certain embodiments, R11is C3-7 cycloalkyl. In certain embodiments, R11is hydroxyl. In certain embodiments, R11is Ci-4alkoxyl. In certain embodiments, R11is selected from the groups depicted in the compounds in Table 1 below.

[0088] As defined generally above, R12and R13are independently hydrogen, C1-6 alkyl, or C3-7 cycloalkyl. In certain embodiments, R12is hydrogen. In certain embodiments, R12is C1-6 alkyl. In certain embodiments, R12is C3-7 cycloalkyl. In certain embodiments, R13is hydrogen. In certain embodiments, R13is C1-6 alkyl. In certain embodiments, R13is C3-7 cycloalkyl. In certain embodiments, R12is selected from the groups depicted in the compounds in Table 1 below. In certain embodiments, R13is selected from the groups depicted in the compounds in Table 1 below.

[0089] As defined generally above,embodiments,certain embodiments, A1is selected from the groups depicted in the compounds in Table 1 below.

[0090] As defined generally above, A2is phenylene, pyridinylene, or naphthalenylene, each of which is substituted with q occurrences of R8. In certain embodiments, A2is phenylene substituted with q occurrences of R8. In certain embodiments, A2is pyridinylene substituted with q occurrences of R8. In certain embodiments, A2is naphthalenylene substituted with q occurrences of R8. In certain embodiments, A2is selected from the groups depicted in the compounds in Table 1 below.

[0091] As defined generally above, L1is -C(O)N(R9)-. In certain embodiments, L1is -C(O)N(R9)-. In certain embodiments, L1is selected from the groups depicted in the compounds in Table 1 below.27168195189 143870-5007-WO

[0092] As defined generally above, X is C1-5 alkylene. In certain embodiments, X is C1-3 alkylene. In certain embodiments, X is -CH2-. In certain embodiments, X is selected from the groups depicted in the compounds in Table 1 below.

[0093] As defined generally above, m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. As defined generally above, n, t, and q are independently 0, 1, or 2. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, t is 0. In certain embodiments, t is 1. In certain embodiments, t is 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2.

[0094] In certain embodiments, the present invention provides a compound of Formula la:or a pharmaceutically acceptable salt thereof, wherein R2, R3, R7, X, A2, and n are as defined above and described in embodiments herein.

[0095] In certain embodiments, the present invention provides a compound of Formula lb:or a pharmaceutically acceptable salt thereof, wherein R2, R3, R7, X, A2, and n are as defined above and described in embodiments herein.

[0096] In certain embodiments, the present invention provides a compound of Formula Ic-1 or Ic-2:28168195189 143870-5007-WOor a pharmaceutically acceptable salt thereof, wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein.

[0097] In certain embodiments, the present invention provides a compound of Formula Ic-1:(Ic-1)or a pharmaceutically acceptable salt thereof, wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein.

[0098] In certain embodiments, the present invention provides a compound of Formula Ic-2:(Ic-2)or a pharmaceutically acceptable salt thereof, wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein.29168195189 143870-5007-WO

[0099] In certain embodiments, the present invention provides a compound of Formula Id:or a pharmaceutically acceptable salt thereof, wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein.

[0100] In certain embodiments, the present invention provides a compound of Formula Ie-1, le- 2, or If, or a pharmaceutically acceptable salt thereof:wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein. In certain embodiments, the compound is selected from a compound in Table 1, or a pharmaceutically acceptable salt thereof.

[0101] In certain embodiments, the present invention provides a compound of Formula Ie-1, or a pharmaceutically acceptable salt thereof:30168195189 143870-5007-WO(Ie-1)wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein. In certain embodiments, the compound is selected from a compound in Table 1, or a pharmaceutically acceptable salt thereof.

[0102] In certain embodiments, the present invention provides a compound of Formula Ie-2, or a pharmaceutically acceptable salt thereof:(Ie-2)wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein. In certain embodiments, the compound is selected from a compound in Table 1, or a pharmaceutically acceptable salt thereof.

[0103] In certain embodiments, the present invention provides a compound of Formula If, or a pharmaceutically acceptable salt thereof:

[0104] wherein R2, R3, R7, X, and A2are as defined above and described in embodiments herein. The description above describes multiple embodiments relating to compounds of31168195189 143870-5007-WOFormula I. The patent application specifically contemplates all combinations of the embodiments.

[0105] In certain embodiments, the compound is one of the following or a pharmaceutically acceptable salt thereof:Exemplary Specific Compounds

[0106] In certain embodiments, the compound is a compound in Table 1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1. In certain embodiments, the compound is any one of compounds I-1 to I-23 in Table 1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is any one of compounds I-1 to I-23 in Table 1.32168195189 143870-5007-WOTABLE 1.33168195189 143870-5007-WO168195189 143870-5007-WO168195189 143870-5007-WO36168195189 143870-5007-WO37168195189 143870-5007-WO168195189 143870-5007-WOSynthetic Methods

[0107] Methods for preparing compounds described herein are illustrated in the following synthetic scheme. The scheme is given for the purpose of illustrating the invention and is not intended to limit the scope or spirit of the invention. Starting materials shown in the scheme can be obtained from commercial sources or can be prepared based on procedures described in the literature.

[0108] The synthetic route illustrated in Scheme 1 is a general method for preparing compound S6 and related compounds. Bromide SI is coupled to boronic ester S2 using Suzuki cross-coupling conditions (e.g., using Pd(dppf)2C12 and K2CO3 in dioxane and H2O at 80 °C, overnight) to afford ester S3. Ester S3 is hydrolyzed (e.g., using LiOH in MeOH) to afford carboxylic acid S4. Carboxylic acid S4 is coupled with compound S5 (e.g., using EDC1, HOBt, and DEA in DMF at room temperature), followed by an intramolecular cyclization under acidic conditions (e.g., using HCl / dioxane and DCM at 0 °C) to afford compound S6 and related compounds.SCHEME 1.

[0109] In the scheme, it is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated (for example, use of protecting groups or alternative reactions). Protecting group chemistry and strategy is well known in the art, for example, as described in detail in Protecting Groups in Organic Synthesis, 3rdEd., T. W. Greene and P. G. M. Wuts, John Wiley & Sons, 1999, and Greene's Protective 39168195189 143870-5007-WOGroups in Organic Synthesis, 5th Ed., (Peter G. M. Wuts, John Wiley & Sons: 2014) the entire contents of both of which are hereby incorporated by reference.

[0110] The modular synthetic route illustrated in the Scheme can also be readily modified by one of skill in the art to provide additional compounds by conducting functional group transformations on the intermediate and final compounds. Such functional group transformations are well known in the art, as described in, for example, Comprehensive Organic Synthesis (B. M. Trost & I. Fleming, eds., 1991-1992); Organic Synthesis, 3rdEd. (Michael B. Smith, Wavefunction, Inc., Irvine: 2010); Modern Methods of Organic Synthesis, 4thEd.(William Carruthers and Iain Coldham, Cambridge University Press, Cambridge: 2004); March ’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 8thEd., (Michael B.Smith, John Wiley & Sons, New York: 2020); and Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 3rd Ed. (Richard C. Larock, ed., John Wiley & Sons, New York: 2018).II. Formulations and Therapeutic Applications

[0111] The invention provides pharmaceutical formulations and methods of treating various diseases, conditions, and disorders. Each are described in more detail below.Pharmaceutically acceptable compositions

[0112] According to another embodiment, the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in compositions of this invention is such that is effective to measurably inhibit USP30 in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this invention is such that is effective to measurably inhibit USP30 in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.

[0113] Another aspect of the provides a pharmaceutical composition comprising a compound described herein (such as a compound of Formula I) and a pharmaceutically acceptable carrier.40168195189 143870-5007-WO

[0114] The term “patient,” as used herein, means an animal, preferably a mammal, and most preferably a human.

[0115] The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0116] A “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.

[0117] As used herein, the term “inhibitorily active metabolite or residue thereof’ means that a metabolite or residue thereof is also an inhibitor of USP30.

[0118] Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution41168195189 143870-5007-WOand isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[0119] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[0120] Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and com starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0121] Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0122] Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.42168195189 143870-5007-WO

[0123] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[0124] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0125] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.

[0126] Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0127] Most preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.

[0128] The amount of compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the 43168195189 143870-5007-WOhost treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01 - 100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.

[0129] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.Uses of Compounds and Pharmaceutically Acceptable Compositions

[0130] Compounds and compositions described herein are generally useful for the inhibition of USP30 and treatment of diseases associated therewith.

[0131] Accordingly, one aspect of the invention provides a method of treating an USP30-mediated disorder, disease, or condition in a patient. The method comprises administering to said patient in need thereof a therapeutically effective amount of a compound described herein (e.g., a compound of Formula I).

[0132] Another aspect of the invention provides a method of inhibiting a USP30 protein. The method comprises contacting a USP30 protein with an effective amount of a compound described herein (e.g., a compound of Formula I) to thereby inhibit the USP30 protein.

[0133] USP30, a deubiquitinase (DUB) localized to mitochondria and peroxisomes is an antagonist of Parkin-mediated mitophagy and of PEX2 -mediated pexophagy. USP30, through its deubiquitinase activity, counteracts ubiquitination and degradation of damaged mitochondria, and inhibition of USP30 rescues mitophagy defects caused by mutant Parkin. Further, inhibition of USP30 decreases oxidative stress and provides protection against the mitochondrial toxin, rotenone. Since damaged mitochondria are more likely to accumulate Parkin, USP30 inhibition should preferentially clear unhealthy mitochondria. USP30 inhibition may beneficially increase rates of basal mitophagy, increase production of mitochondrial derived vesicles, arrest mitochondrial fission and trafficking, and generally improve mitochondrial quality control mechanisms.44168195189 143870-5007-WO

[0134] Without wishing to be bound by any particular theory, it is believed that USP30 inhibitors will promote the clearance of damaged mitochondria to restore mitochondrial homeostasis, attenuating the pathogenic cascade associated with PD pathogenesis.

[0135] In addition to neurons (such as substantia nigra neurons, which are especially vulnerable to mitochondria dysfunction in Parkinson’s disease), long-lived metabolically active cells, such as cardiomyocytes, also rely on an efficient mitochondria quality control system. In this context, Parkin has been shown to protect cardiomyocytes against ischemia / reperfusion injury through activating mitophagy and clearing damaged mitochondria in response to ischemic stress. Thus, inhibitors of USP30 are provided for use in treating conditions involving mitochondrial defects, including neurological conditions, cardiac conditions, and systemic conditions. Deubiquinating enzymes function to oppose the action of the ubiquitinating enzymes in post-translational modification of cellular proteins. These conditions collectively represent examples of age-related disorders and symptoms of natural aging suggesting further utility of USP30 inhibition to slow the process of aging and occurrence of age-related disease. USP30 is a deubiquitinase that is localized to mitochondria and has been shown in expression studies to oppose the action of Parkin-mediated ubiquination and clearance of damaged mitochondria while also opposing basal ubiquitination by ligases such as MUL1 and MARCH5. USP30 that is localized to persoxisomes has been shown to oppose ubiquitination by PEX E3 ligases and induction of selective autophagy.

[0136] In particular, disclosed herein are methods for modulating the activity of USP30 for the treatment of diseases, developmental delays, and symptoms related to mitochondrial dysfunction. For example, the disclosed compounds and compositions are useful in the treatment of mitochondrial diseases, such as Alpers’s Disease, CPEO-Chronic progressive external ophthalmoplegia, Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), MELAS-Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and strokelike episodes, MERRF -Myoclonic epilepsy and ragged-red fiber disease, NARP -neurogenic muscle weakness, ataxia, retinitis pigmentosa, and Pearson Syndrome. Additionally, the disclosed compounds and compositions are useful in the treatment of other USP30-related diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) (Tsubouchi K, Araya J, Kuwano K. “PINK 1-PARK2 -mediated mitophagy in COPD and IPF pathogeneses,” Inflamm Rege. 2018, 35:18. Published 2018 Oct24, doi:10.1186 / s41232-018-0077-6; Kobayashi K., Araya J., Minagawa S., et al. “Involvement of PARK2 -Mediated Mitophagy in Idiopathic 45168195189 143870-5007-WOPulmonary Fibrosis Pathogenesis,” J Immunol. 2016, 797(2):504— 516, doi: 10.4049 / jimmunol.1600265; Ryter S. W., Rosas I. O., Owen C. A., et al. “Mitochondrial Dysfunction as a Pathogenic Mediator of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis,” Ann Am Thorac Soc. 2018, 75(Suppl 4): S266-S272, doi:10.1513 / AnnalsATS.201808-585MG; and Ito S., Araya J., Kurita Y., etal. “PARK2-mediated mitophagy is involved in regulation of HBEC senescence in COPD pathogenesis,” Autophagy.2015, 77(3): 547-559, doi:10.1080 / 15548627.2015.1017190). Alternatively, the disclosed compounds and compositions are useful in the treatment of other USP30-related diseases, such as cardiovascular disease, kidney disease, pulmonary fibrosis, ophthalmic conditions, cancer, cognitive disease, and other related conditions (Lin Q., Li S., Jiang N., et al. “PINK 1 -parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation,” Redox Biol. 2019, 26:101254, doi: 10.1016 / j. redox.2019.101254; Wang Y., Cai J., Tang C., Dong Z. “Mitophagy in Acute Kidney Injury and Kidney Repair,” Cells. 2020, 9(2):338, Published 2020 Feb 1. doi:10.3390 / cells9020338; Wang Y., Tang C., Cai J., et al. “PINKl / Parkin-mediated mitophagy is activated in cisplatin nephrotoxicity to protect against kidney injury,” Cell Death Dis. 2018, 9(11):1113, Published 2018 Nov 1. doi: 10.1038 / s41419-018- 1152-2; and Tang C., Han H., Yan M., et al. “PINK1-PRKN / PARK2 pathway of mitophagy is activated to protect against renal ischemia-reperfusion injury,” Autophagy. 2018, 74(5):880-897, doi:10.1080 / 15548627.2017.1405880). Disclosed compounds are useful in the treatment of peroxisome related diseases such as Ataxia-telangiectasia mutated, Heimler syndrome, Infantile refsum disease, Neonatal adrenoleukodystrophy, Rhizomelic chondrodysplasia punctate, White matter dementia, Zellweger syndrome, and Zellweger spectrum disorders (Riccio et al. “Deubiquitinating enzyme USP30 maintains basal peroxisome abundance by regulating pexophagy,” J Cell Biol. 2019, 275(3):798-807, doi: 10.1083 / jcb.201804172; Marcassa et al. “Dual role of USP30 in controlling basal pexophagy and mitophagy,” EMBO Rep. 2018, 79(7):e45595, doi:10.15252 / embr.201745595; and Nazarko T. Y. “Pexophagy is responsible for 65% of cases of peroxisome biogenesis disorders,” Autophagy. 2017, 73(5):991—994, doi:10.1080 / 15548627.2017.1291480).

[0137] Methods of treating a USP30-related disease or condition in a subject are disclosed. The methods can include administering to the subject an effective amount of one or more compounds46168195189 143870-5007-WOor compositions provided herein. Tn one embodiment, the USP30-related disease is a mitochondrial disease. Examples of mitochondrial diseases include, but are not limited to, Alpers’ Disease, CPEO-Chronic progressive external ophthalmoplegia, Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), MELAS-Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes, MERRF -Myoclonic epilepsy and ragged-red fiber disease, NARP-neurogenic muscle weakness, ataxia, and retinitis pigmentosa, and Pearson Syndrome. In other embodiments, the USP30-related disease is a vascular disease (such as a cardiovascular disease or any disease that would benefit from increasing vascularization in tissues exhibiting impaired or inadequate blood flow). In other embodiments, the USP30-related disease is a muscular disease, such as a muscular dystrophy. Examples of muscular dystrophy include but are not limited to Duchenne muscular dystrophy, Becker muscular dystrophy, limbgirdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. In other embodiments, the USP30-related disease is a form of pulmonary fibrosis. In other embodiments, the USP30-related disease is natural aging or an age-related disease (Sun N., Youle R. J., Finkel T. “The Mitochondrial Basis of Aging,” MolCell.2016, 6 / (5):654-666, doi:10.1016 / j.molcel.2016.01.028; Cornelissen T„ Vilain S., Vints K., Gounko N., Verstreken P., Vandenberghe W. “Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila” Elife. 2018, 7:e35878, Published 2018 May 29. doi: 10.7554 / eLife.35878; Ryu D., Mouchiroud L., Andreux P. A., et al. “Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents,” Nat Med.2016, 22(8):879-888, doi:10.1038 / nm.4132; Brown E. E., Lewin A. S., Ash J. D. “Mitochondria: Potential Targets for Protection in Age-Related Macular Degeneration,” Adv Exp Med Biol. 2018, 1074:11-17, doi: 10.1007 / 978-3-319-75402-4_2; and Ito et al. 2015).

[0138] In certain embodiments, the USP30-related disease or condition is a demyelinating disease, such as multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, or Guillian-Barre syndrome.

[0139] In certain embodiments, the USP30-related disease is a metabolic disease. Examples of metabolic diseases include but are not limited to obesity, hypertriglyceridemia, hyperlipidemia, hypoalphalipoproteinemia, hypercholesterolemia, dyslipidemia, Syndrome X, and Type II diabetes mellitus.47168195189 143870-5007-WO

[0140] In certain embodiments, the USP30-related disease is a muscle structure disorder. Examples of a muscle structure disorders include, but are not limited to, Bethlem myopathy, central core disease, congenital fiber type disproportion, distal muscular dystrophy (MD), Duchenne & Becker MD, Emery-Dreifuss MD, facioscapulohumeral MD, hyaline body myopathy, limb-girdle MD, a muscle sodium channel disorders, myotonic chondrodystrophy, myotonic dystrophy, myotubular myopathy, nemaline body disease, oculopharyngeal MD, and stress urinary incontinence.

[0141] In certain embodiments, the USP30-related disease is a neuronal activation disorder, Examples of neuronal activation disorders include, but are not limited to, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Guillain-Barre syndrome, Lambert-Eaton syndrome, multiple sclerosis, myasthenia gravis, nerve lesion, peripheral neuropathy, spinal muscular atrophy, tardy ulnar nerve palsy, and toxic myoneural disorder. In certain embodiments, the USP30-related disease is a muscle fatigue disorder.

[0142] Examples of muscle fatigue disorders include, but are not limited to chronic fatigue syndrome, diabetes (type I or II), glycogen storage disease, fibromyalgia, Friedreich’s ataxia, intermittent claudication, lipid storage myopathy, MELAS, mucopolysaccharidosis, Pompe disease, and thyrotoxic myopathy.

[0143] In certain embodiments, the USP30-related disease is a muscle mass disorder.

[0144] Examples of muscle mass disorders include, but are not limited to, cachexia, cartilage degeneration, cerebral palsy, compartment syndrome, critical illness myopathy, inclusion body myositis, muscular atrophy (disuse), sarcopenia, steroid myopathy, and systemic lupus erythematosus.

[0145] In certain embodiments, the USP30-related disease is a beta oxidation disease.

[0146] Examples of beta oxidation diseases include, but are not limited to, systemic carnitine transporter, carnitine palmitoyltransferase (CPT) II deficiency, very long-chain acyl-CoA dehydrogenase (LCHAD or VLCAD) deficiency, trifunctional enzyme deficiency, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, short-chain acyl-CoA dehydrogenase (SCAD) deficiency, and riboflavin-responsive disorders of [3-oxidation (RR -MADD).48168195189 143870-5007-WO

[0147] In certain embodiments, the USP30-related disease is a vascular disease. Examples of vascular diseases include, but are not limited to, peripheral vascular insufficiency, peripheral vascular disease, intermittent claudication, peripheral vascular disease (PVD), peripheral artery disease (PAD), peripheral artery occlusive disease (PAOD), and peripheral obliterative arteriopathy.

[0148] In certain embodiments, the USP30-related disease is an ocular vascular disease.

[0149] Examples of ocular vascular diseases include, but are not limited to, age-related macular degeneration (AMD), Stargardt disease, hypertensive retinopathy, diabetic retinopathy, retinopathy, macular degeneration, retinal haemorrhage, and glaucoma.

[0150] In certain embodiments, the USP30-related disease is a muscular eye disease.

[0151] Examples of muscular eye diseases include, but are not limited to, strabismus (crossed eye / wandering eye / walleye ophthalmoparesis), progressive external ophthalmoplegia, esotropia, exotropia, a disorder of refraction and accommodation, hypermetropia, myopia, astigmatism, anisometropia, presbyopia, a disorder of accommodation, or internal ophthalmoplegia. In certain embodiments, the USP30-related disease is a metabolic disease.

[0152] Examples of metabolic disorders include, but are not limited to, hyperlipidemia, dyslipidemia, hyperchlolesterolemia, hypertriglyceridemia, HDL hypocholesterolemia, LDL hypercholesterolemia and / or HLD non-cholesterolemia, VLDL hyperproteinemia, dyslipoproteinemia, apolipoprotein A-I hypoproteinemia, atherosclerosis, disease of arterial sclerosis, disease of cardiovascular systems, cerebrovascular disease, peripheral circulatory disease, metabolic syndrome, syndrome X, obesity, diabetes (type I or II), hyperglycemia, insulin resistance, impaired glucose tolerance, hyperinsulinism, diabetic complication, cardiac insufficiency, cardiac infarction, cardiomyopathy, hypertension, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), thrombus, Parkinson’s disease, Alzheimer’s disease, neurodegenerative disease, demyelinating disease, multiple sclerosis, adrenal leukodystrophy, dermatitis, psoriasis, acne, skin aging, trichosis, inflammation, arthritis, asthma, hypersensitive intestine syndrome, ulcerative colitis, Crohn’s disease, and pancreatitis.

[0153] In certain embodiments, the USP30-related disease is cancer. Examples of cancer include, but are not limited to, cancers of the colon, large intestine, skin, breast, prostate, ovary,49168195189 143870-5007-WOand / or lung. In certain embodiments, the cancer is hepatocellular carcinoma, such as human hepatocellular carcinoma.

[0154] In certain embodiments, the USP30-related disease is an ischemic injury. Examples of ischemic injuries include, but are not limited to, cardiac ischemia, such as myocardial infarction; brain ischemia (e.g., acute ischemic stroke; chronic ischemic of the brain, such as vascular dementia; and transient ischemic attack (TIA); bowel ischemia, such as ischemic colitis; limb ischemia, such as acute arm or leg ischemia; subcutaneous ischemia, such as cyanosis or gangrene; and ischemic organ injury, such as ischemic renal injury (IRI).

[0155] In certain embodiments, the USP30-related disease is a renal disease. Examples of renal diseases include, but are not limited to, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, acute nephritis, recurrent hematuria, persistent hematuria, chronic nephritis, rapidly progressive nephritis, acute kidney injury (also known as acute renal failure), chronic renal failure, diabetic nephropathy, or Bartter’s syndrome. In certain embodiments, the USP30-related disease is chronic kidney disease (CKD), diabetic kidney disease (DKD), Polycystic Kidney Disease (PKD), or igA Nephropathy (igAN). In certain embodiments, the USP30-related disease is glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, acute nephritis, recurrent hematuria, persistent hematuria, chronic nephritis, rapidly progressive nephritis, acute kidney injury, chronic renal failure, diabetic nephropathy, Bartter’s syndrome, chronic kidney disease (CKD), diabetic kidney disease (DKD), Polycystic Kidney Disease (PKD), or igA Nephropathy (igAN).

[0156] In certain embodiments, the USP30-related disease Duchenne Muscular Dystrophy.

[0157] Even though USP30 inhibitors are known in the art, there is a continuing need to provide novel inhibitors having more effective or advantageous pharmaceutically relevant properties. For example, compounds with increased activity, selectivity over other deubiquitinating enzymes (DUBs) such as USP8, USP15, and USP16, and ADMET (absorption, distribution, metabolism, excretion, and / or toxicity) properties. Thus, in some embodiments, the present invention provides inhibitors of USP30 which show selectivity over other DUBs.

[0158] USP8 is a DUB within the same phylogenic tree as USP30, localizes to mitochondria and mediates K6-linked deubiquitination (Kemp M. “Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors,” Prog Med Chem 2016, 55, 149-192). USP8 can also 50168195189 143870-5007-WOdeubiquitinate parkin, thus it may impact the mitophagy pathway. Furthermore, embryonic lethality resulting from USP8 knockout (Niendorf et al., “Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo,” Mol Cell Biol 2007, 27, 5029-5039, PMC 1951504.) suggests USP8 inhibition may have detrimental toxicity. USP15 also localizes to mitochondria and can alter parkin-mediated mitophagy (Coyne and Wing, “The business of deubiquitination — location, location, location,” F1000Res 2016, 5, PMC4755399.). USP16 is similar to USP30 in that they both lack an aspartate as part of their catalytic triad (Gersch et al., “Mechanism and regulation of the Lys6-selective deubiquitinase USP30,” Nat Struct Mol Biol 2017, 24, 920-930, PMC5757785; Nijman et al, “A genomic and functional inventory of deubiquitinating enzymes,” Cell 2005, 123, 773-786; Mevissen and Komander, “Mechanisms of Deubiquitinase Specificity and Regulation,” Annu Rev Biochem 2017, 86, 159-192.) and knockout of this gene is embryonic lethal.

[0159] As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

[0160] Provided compounds are inhibitors of USP30 and are therefore useful for treating one or more disorders associated with activity of USP30. Thus, in certain embodiments, the present invention provides a method for treating a USP30-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.

[0161] As used herein, the term “USP30-mediated” disorders, diseases, and / or conditions as used herein means any disease or other deleterious condition in which USP30 is known to play a role. Accordingly, another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which USP30 is known to play a role.51168195189 143870-5007-WO

[0162] Furthermore, the invention provides the use of a compound according to the definitions herein, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof for the preparation of a medicament for the treatment of a USP30-mediated disorder.Combination Therapies

[0163] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents, which are normally administered to treat that condition, may be administered in combination with compounds and compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”

[0164] In certain embodiments, a provided combination, or composition thereof, is administered in combination with another therapeutic agent.

[0165] Examples of agents the combinations of this invention may also be combined with include, without limitation: treatments for Alzheimer’s Disease such as Aricept® and Excelon®; treatments for HIV such as ritonavir; treatments for Parkinson’s Disease such as L-DOPA / carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), Copaxone®, and mitoxantrone; treatments for asthma such as albuterol and Singulair®; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; agents that prolong or improve pharmacokinetics such as cytochrome P450 inhibitors (i.e., inhibitors of metabolic breakdown) and CYP3A4 inhibitors (e.g., ketokenozole and ritonavir), and agents for treating immunodeficiency disorders such as gamma globulin.52168195189 143870-5007-WO

[0166] In certain embodiments, combination therapies of the present invention, or a pharmaceutically acceptable composition thereof, are administered in combination with a monoclonal antibody or an siRNA therapeutic.

[0167] Those additional agents may be administered separately from a provided combination therapy, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.

[0168] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a combination of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.

[0169] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[0170] In one embodiment, the present invention provides a composition comprising a compound of formula I and one or more additional therapeutic agents. The therapeutic agent may be administered together with a compound of formula I, or may be administered prior to or following administration of a compound of formula I. Suitable therapeutic agents are described in further detail below. In certain embodiments, a compound of formula I may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, a compound of formula I may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours following the therapeutic agent.53168195189 143870-5007-WO

[0171] In another embodiment, the present invention provides a method of treating an inflammatory disease, disorder or condition by administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents. Such additional therapeutic agents may be small molecules or recombinant biologic agents and include, for example, acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, colchicine (Colcrys®), corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, probenecid, allopurinol, febuxostat (Uloric®), sulfasalazine (Azulfidine®), antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®) and auranofin (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®) and “anti-TNF” agents such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), certolizumab pegol (Cimzia®) and adalimumab (Humira®), “anti-ZL-l” agents such as anakinra (Kineret®) and rilonacept (Arcalyst®), canakinumab (Haris®), anti-Jak inhibitors such as tofacitinib, antibodies such as rituximab (Rituxan®), “anti-T-cell” agents such as abatacept (Orencia®), “anti-IL-6” agents such as tocilizumab (Actemra®), diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®), monoclonal antibodies such as tanezumab, anticoagulants such as heparin (Calcinparine® or Liquaemin®) and warfarin (Coumadin®), antidiarrheals such as diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binding agents such as cholestyramine, alosetron (Lotronex®), lubiprostone (Amitiza®), laxatives such as Milk of Magnesia, polyethylene glycol (MiraLax®), Dulcolax®, Correctol® and Senokot®, anticholinergics or antispasmodics such as dicyclomine (Bentyl®), Singulair®, beta-2 agonists such as albuterol (Ventolin® HFA, Proventil® HF A), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol (Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), inhaled corticosteroids such as beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), and flunisolide (Aerobid®), Afviar®, Symbicort®, Dulera®, cromolyn sodium (Intal®), methylxanthines such as theophylline (Theo-Dur®, Theolair®, Slo-bid®, Uniphyl®, Theo-24®)54168195189 143870-5007-WOand aminophylline, IgE antibodies such as omalizumab (Xolair®), nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen®), abacavir / lamivudine (Epzicom®), abacavir / lamivudine / zidovudine (Trizivir®), didanosine (Videx®), emtricitabine (Emtriva®), lamivudine (Epivir®), lamivudine / zidovudine (Combivir®), stavudine (Zerit®), and zalcitabine (Hivid®), non-nucleoside reverse transcriptase inhibitors such as delavirdine (Rescriptor®), efavirenz (Sustiva®), nevairapine (Viramune®) and etravirine (Intelence®), nucleotide reverse transcriptase inhibitors such as tenofovir (Viread®), protease inhibitors such as amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), saquinavir (Fortovase® or Invirase®), and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®), integrase inhibitors such as raltegravir (Isentress®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), bortezomib (Velcade®), and dexamethasone (Decadron ®) in combination with lenalidomide (Revlimid ®), or any combination(s) thereof.

[0172] In another embodiment, the present invention provides a method of treating rheumatoid arthritis comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, sulfasalazine (Azulfidine®), antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®) and auranofin (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®) and “anti-TNF” agents such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), certolizumab pegol (Cimzia®) and adalimumab (Humira®), “anti-lL-1” agents such as anakinra (Kineret®) and rilonacept (Arcalyst®), antibodies such as rituximab (Rituxan®), “anti-T-cell” agents such as abatacept (Orencia®) and “anti-IL-6” agents such as tocilizumab (Actemra®).

[0173] In some embodiments, the present invention provides a method of treating osteoarthritis comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from acetaminophen, non-steroidal anti-inflammatory drugs 55168195189 143870-5007-WO(NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®) and monoclonal antibodies such as tanezumab.

[0174] In some embodiments, the present invention provides a method of treating systemic lupus erythematosus comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from acetaminophen, non-steroidal antiinflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), cyclophosphamide (Cytoxan®), methotrexate (Rheumatrex®), azathioprine (Imuran®) and anticoagulants such as heparin (Calcinparine® or Liquaemin®) and warfarin (Coumadin®).

[0175] In some embodiments, the present invention provides a method of treating Crohn’s disease, ulcerative colitis, or inflammatory bowel disease comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from mesalamine (Asacol®) sulfasalazine (Azulfidine®), antidiarrheals such as diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binding agents such as cholestyramine, alosetron (Lotronex®), lubiprostone (Amitiza®), laxatives such as Milk of Magnesia, polyethylene glycol (MiraLax®), Dulcolax®, Correctol® and Senokot® and anticholinergics or antispasmodics such as dicyclomine (Bentyl®), anti-TNF therapies, steroids, and antibiotics such as Flagyl or ciprofloxacin.

[0176] In some embodiments, the present invention provides a method of treating asthma comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from Singulair®, beta-2 agonists such as albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol (Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), inhaled corticosteroids such as prednisone, prednisolone, beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), flunisolide (Aerobid®), Afviar®, Symbicort®, and Dulera®, cromolyn sodium (Intal®), methylxanthines such as theophylline56168195189 143870-5007-WO(Theo-Dur®, Theolair®, Slo-bid®, Uniphyl®, Theo-24®) and aminophylline, and IgE antibodies such as omalizumab (Xolair®).

[0177] In some embodiments, the present invention provides a method of treating COPD comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from beta-2 agonists such as albuterol (Ventolin® HF A, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol (Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), methylxanthines such as theophylline (Theo-Dur®, Theolair®, Slo-bid®, Uniphyl®, Theo-24®) and aminophylline, inhaled corticosteroids such as prednisone, prednisolone, beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), flunisolide (Aerobid®), Afviar®, Symbicort®, and Dulera®.

[0178] In another embodiment, the present invention provides a method of treating a hematological malignancy comprising administering to a patient in need thereof a compound of formula 1 and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK / pan-JAK inhibitor, a PI3K inhibitor, a SYK inhibitor, and combinations thereof.

[0179] In another embodiment, the present invention provides a method of treating a solid tumor comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK / pan-JAK inhibitor, a PI3K inhibitor, a SYK inhibitor, and combinations thereof.

[0180] In another embodiment, the present invention provides a method of treating a hematological malignancy comprising administering to a patient in need thereof a compound of formula I and a Hedgehog (Hh) signaling pathway inhibitor. In some embodiments, the hematological malignancy is DLBCL (Ramirez et al “Defining causative factors contributing in57168195189 143870-5007-WOthe activation of hedgehog signaling in diffuse large B-cell lymphoma,” Leuk. Res. 2012, published online July 17, and incorporated herein by reference in its entirety).

[0181] In another embodiment, the present invention provides a method of treating diffuse large B-cell lymphoma (DLBCL) comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, and combinations thereof.

[0182] In another embodiment, the present invention provides a method of treating multiple myeloma comprising administering to a patient in need thereof a compound of formula I and one or more additional therapeutic agents selected from bortezomib (Velcade®), and dexamethasone (Decadron®), a hedgehog signaling inhibitor, a BTK inhibitor, a JAK / pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor in combination with lenalidomide (Revlimid®).

[0183] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula I and a BTK inhibitor, wherein the disease is selected from inflammatory bowel disease, arthritis, systemic lupus erythematosus (SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still’s disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto’s thyroiditis, Ord’s thyroiditis, Graves’ disease, autoimmune thyroiditis, Sjogren’s syndrome, multiple sclerosis, systemic sclerosis, Lyme neuroborreliosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison’s disease, opsoclonus-myoclonus syndrome, ankylosing spondylosis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture’s syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter’s syndrome, Takayasu’s arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener’s granulomatosis, psoriasis, alopecia universalis, Behcet’s disease, chronic fatigue, dysautonomia, membranous glomerulonephropathy, endometriosis, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, vulvodynia, a hyperproliferative disease, rejection of transplanted organs or tissues, Acquired Immunodeficiency Syndrome (AIDS, also known as HIV), type 1 diabetes, graft versus host disease, transplantation, transfusion, anaphylaxis, allergies (e.g., allergies to plant pollens,58168195189 143870-5007-WOlatex, drugs, foods, insect poisons, animal hair, animal dander, dust mites, or cockroach calyx), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis, asthma, appendicitis, atopic dermatitis, asthma, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn’s disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henoch-Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis, B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also known as plasma cell myeloma), non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, Burkitt lymphoma / leukemia, or lymphomatoid granulomatosis, breast cancer, prostate cancer, or cancer of the mast cells (e.g, mastocytoma, mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone cancer, colorectal cancer, pancreatic cancer, diseases of the bone and joints including, without limitation, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter’s disease), Behcet’s disease, Sjogren’s syndrome, systemic sclerosis, osteoporosis, bone cancer, bone metastasis, a thromboembolic disorder, (e.g, myocardial infarct, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, deep venous thrombosis), inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitus, agammaglobulinemia, psoriasis, allergy,59168195189 143870-5007-WOCrohn’s disease, irritable bowel syndrome, ulcerative colitis, Sjogren’s disease, tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture’s syndrome, atherosclerosis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, septic shock, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto’s thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Guillain-Barre syndrome, Behcet’s disease, scleraderma, mycosis fungoides, acute inflammatory responses (such as acute respiratory distress syndrome and ischemia / reperfusion injury), and Graves’ disease.

[0184] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula I and a PI3K inhibitor, wherein the disease is selected from a cancer, a neurodegenative disorder, an angiogenic disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathologic immune conditions involving T cell activation, a cardiovascular disorder, and a CNS disorder.

[0185] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula I and a PI3K inhibitor, wherein the disease is selected from benign or malignant tumor, carcinoma or solid tumor of the brain, kidney (e.., renal cell carcinoma (RCC)), liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testis, genitourinary tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character,60168195189 143870-5007-WOadenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, nonsmall-cell lung carcinoma, lymphomas, (including, for example, non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s lymphoma (also termed Hodgkin’s or Hodgkin’s disease)), a mammary carcinoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, or a leukemia, diseases include Cowden syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome, or diseases in which the PI3K / PKB pathway is aberrantly activated, asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection, acute lung injury (ALI), adult / acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy, bronchitis of whatever type or genesis including, but not limited to, acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis, pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis, Loffler’s syndrome, eosinophilic, pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or etiology, including autoimmune hematological disorders (e.g, hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia), systemic lupus erythematosus, rheumatoid arthritis, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g, ulcerative colitis and61168195189 143870-5007-WOCrohn’s disease), endocrine opthalmopathy, Grave’s disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change nephropathy, restenosis, cardiomegaly, atherosclerosis, myocardial infarction, ischemic stroke and congestive heart failure, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity and hypoxia.

[0186] In some embodiments the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula I and a Bcl-2 inhibitor, wherein the disease is an inflammatory disorder, an autoimmune disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation. In some embodiments, the disorder is a proliferative disorder, lupus, or lupus nephritis. In some embodiments, the proliferative disorder is chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Hodgkin’s disease, small-cell lung cancer, non-smallcell lung cancer, myelodysplastic syndrome, lymphoma, a hematological neoplasm, or solid tumor.

[0187] In some embodiments the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula I and a parkin activator, wherein the disease is an inflammatory disorder, an autoimmune disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation. In some embodiments, the disorder is a neurological disorder. In some embodiments, the disorder is Parkinson’s disease. In some embodiments, the disorder is Alzheimer’s disease.

[0188] The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent,62168195189 143870-5007-WOits mode of administration, and the like. Compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “patient,” as used herein, means an animal, preferably a mammal, and most preferably a human.

[0189] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg / kg to about 50 mg / kg and preferably from about 1 mg / kg to about 25 mg / kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

[0190] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.63168195189 143870-5007-WO

[0191] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution, U. S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0192] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0193] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0194] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.64168195189 143870-5007-WO

[0195] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0196] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[0197] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and 65168195189 143870-5007-WOmicrocrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0198] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0199] According to one embodiment, the invention relates to a method of inhibiting USP30 activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.

[0200] According to another embodiment, the invention relates to a method of inhibiting USP30 activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound. In certain embodiments, the invention relates to a method of irreversibly inhibiting USP30, or a mutant thereof, activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.

[0201] In another embodiment, the invention provides a method of selectively inhibiting USP30 over one or more DUBs. In some embodiments, a compound of the present invention is more than 2-fold selective over USP8, USP15, and / or USP 16. In some embodiments, a compound of the present invention is more than 5-fold selective over USP8, USP15, and / or USP16. In some embodiments, a compound of the present invention is more than 10-fold selective over USP8,66168195189 143870-5007-WOUSP15, and / or USP16. In some embodiments, a compound of the present invention is more than 50-fold selective over USP8, USP15, and / or USP16. In some embodiments, a compound of the present invention is more than 100-fold selective over USP8, USP15, and / or USP16.

[0202] The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

[0203] Inhibition of USP30 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include but are not limited to biological assays.

[0204] Another embodiment of the present invention relates to a method of inhibiting USP30 activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.

[0205] According to another embodiment, the invention relates to a method of inhibiting activity of USP30 in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound. According to certain embodiments, the invention relates to a method of reversibly or irreversibly inhibiting USP30 activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound. In other embodiments, the present invention provides a method for treating a disorder mediated by USP30 in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof. Such disorders are described in detail herein.

[0206] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents that are normally administered to treat that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”

[0207] A compound of the current invention may also be used to advantage in combination with other therapeutic compounds. In some embodiments, the other therapeutic compounds are antiproliferative compounds. Such antiproliferative compounds include, but are not limited to67168195189 143870-5007-WOaromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; anti neoplastic antimetabolites; platin compounds; compounds targeting / decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; antiandrogens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17 -DMAG ( 17-dimethyl aminoethylamino- 17-demethoxy-gel danamy cin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temozolomide (Temodal®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentami dine / chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array BioPharma, AZD6244 from AstraZeneca, PD181461 from Pfizer and leucovorin. The term “aromatase inhibitor” as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name Aromasin™ Formestane is marketed under the trade name Lentaron™. Fadrozole is marketed under the trade name Afema™. Anastrozole is marketed under the trade name Arimidex™ Letrozole is marketed under the trade names Femara™ or Femar™. Aminoglutethimide is marketed under the trade name Orimeten™. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.

[0208] The term “anti estrogen” as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed under the trade name68168195189 143870-5007-WONolvadex™ Raloxifene hydrochloride is marketed under the trade name Evista™. Fulvestrant can be administered under the trade name Faslodex™. A combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors.

[0209] The term “anti-androgen” as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (Casodex™). The term “gonadorelin agonist” as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin can be administered under the trade name Zoladex™.

[0210] The term “topoisomerase I inhibitor” as used herein includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark Camptosar™. Topotecan is marketed under the trade name Hycamptin™.

[0211] The term “topoisomerase II inhibitor” as used herein includes but is not limited to the anthracyclines, such as doxorubicin (including liposomal formulation, such as Caelyx™), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name Etopophos™. Teniposide is marketed under the trade name VM 26-Bristol Doxorubicin is marketed under the trade name Acriblastin ™ or Adriamycin™. Epirubicin is marketed under the trade name Farmorubicin™. Idarubicin is marketed, under the trade name Zavedos™. Mitoxantrone is marketed under the trade name Novantron.

[0212] The term “microtubule active agent” relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof. Paclitaxel is marketed under the trade name Taxol™. Docetaxel is marketed under the trade name Taxotere™. Vinblastine sulfate is marketed under the trade name Vinblastin R. P™. Vincristine sulfate is marketed under the trade name Farmistin™.69168195189 143870-5007-WO

[0213] The term “alkylating agent” as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name Cyclostin™. Ifosfamide is marketed under the trade name Holoxan™.

[0214] The term “histone deacetylase inhibitors” or “HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).

[0215] The term “antineoplastic antimetabolite” includes, but is not limited to, 5 -fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name Xeloda™. Gemcitabine is marketed under the trade name Gemzar™

[0216] The term “platin compound” as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark Carboplat™. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark Eloxatin™.

[0217] The term “compounds targeting / decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti -angiogenic compounds” as used herein includes, but is not limited to, protein tyrosine kinase and / or serine and / or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an A-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the kinase activity of IGF-I receptor, or antibodies that target the extracellular domain of IGF-I receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the Axl receptor70168195189 143870-5007-WOtyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the activity of the Kit / SCFR receptor tyrosine kinase, such as imatinib; h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases, which are part of the PDGFR family, such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, such as imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine / threonine kinases, members of the MEK, SRC, JAK / pan-JAK, FAK, PDK1, PKB / Akt, Ras / MAPK, PI3K, SYK, BTK and TEC family, and / or members of the cyclin-dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; LY333531 / LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (Gleevec™) or tyrphostin such as Tyrphostin A23 / RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-{[(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR₁ ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, such as EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, CP 358774, ZD 1839, ZM 105180; trastuzumab (Herceptin™), cetuximab (Erbitux™), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569,71168195189 143870-5007-WOGW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 orE7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF, n) compounds targeting, decreasing or inhibiting the kinase activity of one or more JAK family members (JAK1 / JAK2 / JAK3 / TYK2 and / or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib, and ruxolitinib; o) compounds targeting, decreasing or inhibiting the kinase activity of PI3 kinase (PI3K) including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL- 147, XL-765, and idelalisib; and; and q) compounds targeting, decreasing or inhibiting the signaling effects of hedgehog protein (Hh) or smoothened receptor (SMO) pathways, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib, and IPI-926 (saridegib).

[0218] The term “PI3K inhibitor” as used herein includes but is not limited to compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3 -kinase family, including, but not limited to PI3Ka, PI3Ky, PI3K5, PI3K, PI3K-C2a, PI3K-C2, PI3K-C2y, Vps34, pl 10-a, pl 10-P, pl 10-y, pl 10-5, p85-a, p85-P, p55-y, pl 50, pl 01, andp87. Examples of PI3K inhibitors useful in this invention include but are not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib.

[0219] The term “BTK inhibitor” as used herein includes but is not limited to compounds having inhibitory activity against Bruton’s Tyrosine Kinase (BTK), including, but not limited to AVL-292 and ibrutinib.

[0220] The term “SYK inhibitor” as used herein includes but is not limited to compounds having inhibitory activity against spleen tyrosine kinase (SYK), including but not limited to PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.

[0221] The term “Bcl-2 inhibitor” as used herein includes but is not limited to compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including but not limited to ABT-199, ABT-731, ABT-737, apogossypol, Ascenta’s pan-Bcl-2 inhibitors, curcumin (and72168195189 143870-5007-WOanalogs thereof), dual Bcl-2 / Bcl-xL inhibitors (Infinity Pharmaceuticals / Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and analogs thereof; see W02008118802), navitoclax (and analogs thereof, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and analogs thereof, see W02004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ, of Michigan), and venetoclax. In some embodiments the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments the Bcl-2 inhibitor is a peptidomimetic.

[0222] Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02008039218 and WO2011090760, the entirety of which are incorporated herein by reference.

[0223] Further examples of SYK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02003063794, W02005007623, and W02006078846, the entirety of which are incorporated herein by reference.

[0224] Further examples of PI3K inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02004019973, W02004089925, W02007016176, US8138347, W02002088112, W02007084786, W02007129161, W02006122806, W02005113554, and W02007044729 the entirety of which are incorporated herein by reference.

[0225] Further examples of JAK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02009114512, W02008109943, W02007053452, W02000142246, and W02007070514, the entirety of which are incorporated herein by reference.

[0226] Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e g. thalidomide (Thalomid™) and TNP-470.

[0227] Examples of proteasome inhibitors useful for use in combination with compounds of the invention include, but are not limited to bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, andMLN9708.73168195189 143870-5007-WO

[0228] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g., inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.

[0229] Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, a- y- or 8- tocopherol or a- y- or 8-tocotrienol.

[0230] The term cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (Celebrex™), rofecoxib (Vioxx™), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenyl acetic acid, lumiracoxib.

[0231] The term “bisphosphonates” as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid. Etridonic acid is marketed under the trade name Didronel™. Clodronic acid is marketed under the trade name Bonefos™. Tiludronic acid is marketed under the trade name Skelid™. Pamidronic acid is marketed under the trade name Aredia™. Alendronic acid is marketed under the trade name Fosamax™. Ibandronic acid is marketed under the trade name Bondranat™. Risedronic acid is marketed under the trade name Actonel™. Zoledronic acid is marketed under the trade name Zometa™. The term “mTOR inhibitors” relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (Certican™), CCI-779 and ABT578.

[0232] The term “heparanase inhibitor” as used herein refers to compounds which target, decrease or inhibit heparin sulfate degradation. The term includes, but is not limited to, PI-88. The term “biological response modifier” as used herein refers to a lymphokine or interferons.

[0233] The term “inhibitor of Ras oncogenic isoforms,” such as H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras; for example, a “farnesyl transferase inhibitor” such as L-744832, DK8G557 or R115777 (Zamestra™). The term “telomerase inhibitor” as used herein refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, such as telomestatin.74168195189 143870-5007-WO

[0234] The term “methionine aminopeptidase inhibitor” as used herein refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or a derivative thereof.

[0235] The term “proteasome inhibitor” as used herein refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include, but are not limited to, Bortezomib (Velcade™) and MLN 341.

[0236] The term “matrix metalloproteinase inhibitor” or (“MMP” inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211, MMI270B or AAJ996.

[0237] The term “compounds used in the treatment of hematologic malignancies” as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1-P-D-arabinofuransylcytosine (ara-c) and bisulfan; ALK inhibitors, which are compounds which target, decrease or inhibit anaplastic lymphoma kinase, and Bcl-2 inhibitors.

[0238] Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine derivative, SU11248 andMLN518.

[0239] The term “HSP90 inhibitors” as used herein includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, such as 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HD AC inhibitors.75168195189 143870-5007-WO

[0240] The term “antiproliferative antibodies” as used herein includes, but is not limited to, trastuzumab (Herceptin™), Trastuzumab-DMl, erbitux, bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody. By antibodies is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.

[0241] For the treatment of acute myeloid leukemia (AML), compounds of the current invention can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of the current invention can be administered in combination with, for example, farnesyl transferase inhibitors and / or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum andPKC412. In certain embodiments, the present invention provides a method of treating AML associated with an ITD and / or D835Y mutation, comprising administering a compound of the present invention together with a one or more FLT3 inhibitors. In certain embodiments, the FLT3 inhibitors are selected from quizartinib (AC220), a staurosporine derivative (e.g. midostaurin or lestaurtinib), sorafenib, tandutinib, LY-2401401, LS-104, EB-10, famitinib, NOV-110302, NMS-P948, AST-487, G-749, SB-1317, S-209, SC-110219, AKN-028, fedratinib, tozasertib, and sunitinib. In certain embodiments, the FLT3 inhibitors are selected from quizartinib, midostaurin, lestaurtinib, sorafenib, and sunitinib.

[0242] Other anti-leukemic compounds include, for example, Ara-C, a pyrimidine analog, which is the 2’ -alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate. Compounds which target, decrease or inhibit activity of histone deacetylase (HD AC) inhibitors such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the activity of the enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065 including, but not limited to, A hydroxy-3-[4-[[[2-(2-methyl- l / 7-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and 7V-hydroxy-3-[4-[(2-hydroxyethyl){2-(l / 7-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt. Somatostatin receptor antagonists as used herein refer to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230. Tumor cell damaging approaches refer to approaches 76168195189 143870-5007-WOsuch as ionizing radiation. The term “ionizing radiation” referred to above and hereinafter means ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et aL, Eds., 4thEdition, Vol. 1, pp. 248-275 (1993).

[0243] Also included are EDG binders and ribonucleotide reductase inhibitors. The term “EDG binders” as used herein refers to a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720. The term “ribonucleotide reductase inhibitors” refers to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and / or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and / or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-17 / -isoindole-l,3-dione derivatives.

[0244] Also included are in particular those compounds, proteins or monoclonal antibodies of VEGF such as l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; Angiostatin™; Endostatin™; anthranilic acid amides; ZD4190; ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibody, Angiozyme (RPT 4610) and Bevacizumab (Avastin™).

[0245] Photodynamic therapy as used herein refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as Visudyne™ and porfimer sodium.

[0246] Angiostatic steroids as used herein refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 11-a-epihydrocotisol, cortexolone, 17a-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.

[0247] Implants containing corticosteroids refers to compounds, such as fluocinolone and dexamethasone.77168195189 143870-5007-WO

[0248] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.

[0249] The compounds of the invention are also useful as co-therapeutic compounds for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs. A compound of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. Accordingly, the invention includes a combination of a compound of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound of the invention and said drug substance being in the same or different pharmaceutical composition.

[0250] Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; non-steroidal glucocorticoid receptor agonists; LTB4 antagonists such LY293111, CGS025019C, CP-195543, SC-53228, BITL 284, ONO 4057, SB 209247; LTD4 antagonists such as montelukast and zafirlukast; PDE4 inhibitors such cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden), V-l 1294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering- Plough), Arofylline (Almirall Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12- 281 (Asta Medica), CDC-801 (Celgene), SelCID(TM) CC-10004 (Celgene), VM554 / UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo); A2a agonists; A2b antagonists; and beta-2 adrenoceptor agonists such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol and pharmaceutically acceptable salts thereof. Suitable bronchodilatory drugs include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate.78168195189 143870-5007-WO

[0251] Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine.

[0252] Other useful combinations of compounds of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g. CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-351125, SCH- 55700 and SCH-D, and Takeda antagonists such as A-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5Z7-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-V, A-dimethyl-2 / 7-pyran-4-aminium chloride (TAK-770).

[0253] The structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium “The Merck Index” or from databases, e.g. Patents International (e.g. IMS World Publications).

[0254] A compound of the current invention may also be used in combination with known therapeutic processes, for example, the administration of hormones or radiation. In certain embodiments, a provided compound is used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

[0255] A compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds. A compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.79168195189 143870-5007-WO

[0256] Those additional agents may be administered separately from an inventive compoundcontaining composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.

[0257] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0258] The amount of both an inventive compound and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg / kg body weight / day of an inventive compound can be administered.

[0259] In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 pg / kg body weight / day of the additional therapeutic agent can be administered.

[0260] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.80168195189 143870-5007-WO

[0261] The invention further provides a unit dosage form (such as a tablet or capsule) comprising a compound described herein in a therapeutically effective amount for the treatment of a medical disorder described herein.EXAMPLES

[0262] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and is not intended to limit the invention.

[0263] The following abbreviations are used herein: Bipy.: bipyridine; BSA: bovine serum albumin; DAST: diethylaminosulfur trifluoride; DBU: l,8-diazabicyclo[5.4.0]undec-7-ene; DCM: dichloromethane; DHAP: 2,5-dihydroxyacetophenone; DIEA: diisopropylethylamine; DIBAL-H: diisobutylaluminium hydride; DIPEA: diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: A, A-dimethylformamide; DMP: Dess-Martin periodinane;DMPU: / V, / V -di methyl propyleneurea, DMSO: dimethylsulfoxide; DTT: dithiothreitol; DUB: deubiquitinating enzyme; EA or EtOAc: ethyl acetate; EDC1: 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide; equiv. or eq.: molar equivalents; FA: formic acid; h: hour or hours; HOBt: hydroxybenzotriazole; HPLC: high-pressure liquid chromatography; iPrOH: isopropyl alcohol; LCMS orLC-MS: liquid chromatography-mass spectrometry; MALDI-TOF: matrix-assisted laser desorption / ionizati on-time of flight; MeCN: acetonitrile; MeOH: methanol; MS: mass spectrometry; Ms: methanesulfonyl; NMR: nuclear magnetic resonance; PE: petroleum ether; Py.: pyridine; rt: room temperature; t-Bu: tert-butyl; TEA: tri ethylamine; TFA: trifluoroacetic acid; THF: tetrahydrofuran; TRIS: tris(hydroxymethyl)aminomethane; and USP30: Ubiquitin-specific protease 30.EXAMPLE 1 - Syntheses of (1R*, 2S*)-2-methoxycyclopropan-l-amine hydrochloride and (IS*, 2R*)-2-andnocyclopropan-l-ol hydrochloride)Step 1 Step 281168195189 143870-5007-WOp Step 3relative stereochemistryCis cyclopropylRelative StereochemistryCis

[0264] Step 1: Synthesis of (E')-A-allyl-l-phenylmethanimine. To a solution of benzaldehyde (9.0 g, 84.9 mmol, 1. 0 eq.) and prop-2-en-l-amine hydrochloride (7.8 g, 84.9 mmol, 1. 0 eq.) in DCM (150 mL) was added MgSC>4(20.5 g, 170 mmol, 2. 0 eq.) and TEA (17.1 g, 170 mmol, 2. 0 eq.). The mixture was stirred at room temperature for 17 hours. The resulting mixture was filtered. The filtrate was washed with brine (2 x 100 mL), dried over anhydrous Na2SO4, and concentrated in vacuo to afford crude (£)-A-al lyl -1 -phenyl methanimine (12 g, quantitative), which was used in the next step without further purification.1H NMR (400 MHz, CDCI3) 58.32 (s, 1H), 7.78 (dd, J= 6.6, 3.1 Hz, 2H), 7.44 (dd, J= 5.1, 1.8 Hz, 3H), 6.10 (ddd, J= 22.7, 10.8, 5.7 Hz, 1H), 5.36 - 5.08 (m, 2H), 4.29 (ddd, J= 5.6, 3.0, 1.5 Hz, 2H).

[0265] Step 2: Synthesis of (£)-7V-(3-bromo-2-methoxypropyl)-l-phenylmethanimine. To a solution of (E)-A-allyl-l-phenylmethanimine (12.0 g, 82.7 mmol, 1. 0 eq.) in MeOH (150 mL) was added NBS (14.7 g, 82.7 mmol, 1. 0 eq.) in portions at 0 °C under nitrogen. The reaction was stirred at room temperature for 17 hours. The resulting mixture was concentrated in vacuo to afford crude (E)-N-(3-bromo-2-methoxypropyl)-1-phenylmethanimine (26 g, quantitative), which was used in the next step without further purification. MS (ESI+) m / z 256.2 [M+l]+.

[0266] Step 3: Synthesis of25*)-2-methoxycyclopropyl)-l-phenylmethanimine. To a solution of (£)-A-(3-bromo-2-methoxypropyl)-l-phenylmethanimine (13.0 g, 30.9 mmol, 1.0 eq.) in Et2O (150 mL) was added tBuOK (17.1 g, 153 mmol, 3. 0 eq.) in portions at room temperature under nitrogen. The reaction was stirred at 36 °C for 3 hours. The resulting mixture was washed with brine (2 x 50 mL), extracted with EA (2 x 50 mL), dried over82168195189 143870-5007-WOanhydrous Na2SC>4, and concentrated in vacuo to provide crude (A)-A-((17?*,2S*)-2-methoxycyclopropyl)-l-phenylmethanimine (13.0 g, quantitative), which was used in the next step without further purification. MS (ESI+) m / z 176.2 [M+1]+.

[0267] Step 4: Synthesis of (11?*, 2S*)-2-methoxycyclopropan-l-amine hydrochloride and: (15*, 21?*)-2-aminocyclopropan-l-ol hydrochloride. To a solution of (£)- / V-(3-bromo-2-methoxypropyl)-l-phenylmethanimine (13.0 g, 73.9 mmol, 1.0 eq.) in Et2O (50 mL) was added aqueous HC1 (2 N, 50 mL) at room temperature. The reaction was stirred at 36 °C for 18 hours. The resulting mixture was extracted with DCM (2 x 50 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo to provide a mixture of ( 1R *, 2S*)-2-m ethoxy cyclopropan-1 -amine hydrochloride and (IS* 27?*)-2-aminocyclopropan-l-ol hydrochloride (2.2 g, 24% yield), which was used without further purification and carried forward as a mixture. MS (ESI+) m / z 88.2 [M+l]+.EXAMPLE 2 - Synthesis of (IS*, 2S*)-2-((tert-butyldimethylsilyl)oxy)cyclopropan-l-amine)trans relative stereochemistry

[0268] A solution of 2-((lS*,2S*)-2-(( / ert-butyldimethylsilyl)oxy)cyclopropyl)isoindoline-1, 3-dione (2.2 g, 6.9 mmol, 1.0 eq.) and hydrazine hydrate (1.73 g, 34.7 mmol, 5. 0 eq.) in DCM / EtOH (10 / 20 mL) was stirred at room temperature for 4 hours. The mixture was filtered, and the filtrate was concentrated in vacuo to afford crude (IS*, 2S*)-2-((terZ-butyldimethylsilyl)oxy)cyclopropan-l-amine (1.8 g, quantitative), which was used in the next step without further purification. MS (ESI+) / w / z 188.2 [M+l]+.83168195189 143870-5007-WOEXAMPLE 3 - Synthesis of (IS*, 2R*)-2-((tert-butyldimethylsilyl)oxy)cyclopropan-l -amine hydrochlorideCis relative stereochemistry

[0269] A solution of 2-((15'*,27?*)-2-(( / ert-butyldimethylsilyl)oxy)cyclopropyl)isoindoline- 1, 3-dione (400 mg, 1.26mmol, 1. 0 eq.) and hydrazine hydrate (315 mg, 6.3 mmol, 5. 0 eq.) in DCM / EtOH (2 / 4 mL) was stirred at room temperature for 4 hours. The mixture was filtered, and the filtrate was concentrated in vacuo to afford crude (lS*,2A*)-2-((ter / - butyldimethylsilyl)oxy)cyclopropan-l-amine hydrochloride (230 mg, quantitative), which was used in the next step without further purification. MS (ESI+) m / z 188.2 [M+l]+.EXAMPLE 4 - Synthesis of (lR*,2S*)-2-((tert-hutyldimethylsilyl)oxy)cyclohiitan-l-amineCis relative stereochemistry trans relative stereochemistryC D, r.C Cis relative stereochemistry

[0270] Step 1: Synthesis of 2-hydroxycyclobutan-l-one. To a solution of 1,2- Z> A((trimethylsilyl)oxy)cyclobut-l-ene (3.0 g, 13.0 mmol, 1.0 eq.) in acetone (30 mL) was added H2O (0.47 mL, 26.0 mmol, 2.0 eq.) and FeCh / SiCh (50 mg) at room temperature. The reaction was stirred at room temperature for 2 hours, dried over anhydrous Na2SC>4, and filtered through a84168195189 143870-5007-WOpad of celite. The filtrate was concentrated in vacuo to provide 2-hydroxycyclobutan-l-one as a light-yellow solid (1.22 g, crude).

[0271] Step 2: Synthesis of 2-(dibenzylamino)cyclobutan-l-one. Dibenzylamine (2.49 mL, 12.96 mmol, 1.00 eq.) was added dropwise to a solution of 2-hydroxycyclobutan-l-one (1.228 g, 14.26 mmol, 1.10 eq.) and DMAP (316.7 mg, 2.59 mmol, 0.20 eq.) in toluene (30 mL) at room temperature. The reaction was stirred at room temperature overnight, concentrated in vacuo, and purified by flash column chromatography (10% EA / PA) to provide 2-(dibenzylamino)cyclobutan-1-one as a light-yellow oil (2.09 g, 60.7% yield). MS (ESL): m / z 266.2 [M+H]+.

[0272] Step 3: Synthesis of (ll?*,2 '*)-2-(dibenzylamino)cyclobutan-l-ol & (15*,25*)-2-(dibenzylamino)cyclobutan-l-ol. NaBlL (216.9 mg, 5.73 mmol, 1.0 eq.) was added in portions to a solution of 2-(dibenzylamino)cyclobutan-l-one (1.522 g, 5.73 mmol, 1.0 eq.) in MeOH (30 mL) at 0 °C. The reaction was stirred at room temperature for 2 hours. The reaction was then quenched with water, extracted with EA (3 x 20 mL), washed with brine (2 x 20 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, EA / PE) and C was eluted in 14% EA in PE to provide (lR*,2S*)-2-(dibenzylamino)cyclobutan-l-ol (476.8 mg, 31.1 % yield) as a light-yellow oil. MS (ES1+) m / z 268.2 [M+l]+. ‘HNMR (400 MHz, DMSO-d6) 5 7.36 - 7.28 (m, 8H), 7.23 (td, J= 4.5, 3.1 Hz, 2H), 4.64 (d, J= 5.7 Hz, 1H), 4.21 (dd, J= 5.2, 3.0 Hz, 1H), 3.63 (d, J= 14.0 Hz, 2H), 3.49 (d, J = 14.1 Hz, 2H), 3.14 - 3.00 (m, 1H), 2.15 - 2.01 (m, 1H), 1.95 - 1.77 (m, 2H), 1.60 (t, J= 10.0 Hz, 1H).

[0273] Elution with 17% EA in PE provided (lS*,25*)-2-(dibenzylamino)cyclobutan-l-ol as a light-yellow oil (626.8 mg, 40.91 % yield). MS (ESI+) m / z 268.2 [M+l]+.1H NMR (400 MHz, DMSO) 87.31 (d, J= 4.4 Hz, 8H), 7.22 (dd, J= 8.7, 4.4 Hz, 2H), 5.16 (d, J= 7.2 Hz, 1H), 3.91 (p, J= 7.5 Hz, 1H), 3.62 (d, J= 14.1 Hz, 2H), 3.42 (d, J= 14.1 Hz, 2H), 2.91 (dd, J= 16.0, 7.8 Hz, 1H), 1.93 (dd, J= 17.8, 8.7 Hz, 1H), 1.61 (dd, J= 18.1, 9.0Hz, 1H), 1.38 - 1.28 (m, 1H), 1.11 (d, J = 9.2 Hz, 1H).

[0274] Step 4: Synthesis of tert-butyl (1?*,25*)-V, A-dibenzyl-2-((tert-butyldiinethylsilyl)oxy)cyclobutan-l-amine. A solution of 177-imidazole (364.2 mg, 5.35 mmol, 3.0 eq.) in DMF (1 mL) was added to a solution of (15*,27?*)-2-(dibenzylamino)cyclobutan-l-ol (476.8 mg, 1.78 mmol, 1.00 eq.) and TBSC1 (537.6 mg, 3.57 mmol, 2.0 eq.) in DMF (10 mL) at85168195189 143870-5007-WOroom temperature under N2 atmosphere. The reaction was stirred at room temperature overnight. The reaction was then quenched with water, extracted with DCM (3 x 20 mb), washed with brine (2 x 20 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 5% EA / PE to 8 % EA / PE) to afford (17?*,2S*)- / V, / V- dibenzyl-2-((te / 7-butyldimethylsilyl)oxy)cyclobutan-l -amine as a colorless oil (593.0 mg, 87.3 % yield). MS (ESI+) TW / Z 382.2 [M-100+l]+.

[0275] Step 5: Synthesis of (ll?*,25*)-2-((tert-butyldimethylsilyl)oxy)cyclobutan-l-amine. Pd / C (79.9 mg, 0.075 mmol, 0.1 eq.) was added to a solution of (l / ?*,2, S'*)-N,N-dibenzyl-2-((tert- butyldimethylsilyl)oxy)cyclobutan-l -amine (287.8 mg, 0.75 mmol, 1.0 eq.) in MeOH (10 mL). The reaction was stirred at 35 °C under an atmosphere of H2 overnight. Then, the reaction was filtered and concentrated in vacuo to provide (17?*,2 *)-2-((ter / - butyldimethylsilyl)oxy)cyclobutan-l -amine as a colorless oil (154.6 mg, crude). MS (ESI+) m / z 202.2 [M+l]+.EXAMPLE 5 - Synthesis of (lS*,2S*)-2-((tert-hutyldimethylsilyl)oxy)cyclobutan-l-amineTrans relative stereochemistry

[0276] The title compound was synthesized via the same method as Example 4 by using (l *,2S*)-2-(dibenzylamino)cyclobutan-l-ol (D).EXAMPLE 6 — Synthesis of (E)-2-(2-ethoxyvinyl)-4-fluorobenzoic acid

[0277] Step 1: Synthesis of ethyl (£)-2-(2-ethoxyvinyl)-4-fluorobenzoate. Pd(dppf)2C12. DCM (510 mg, 0.63 mmol, 0.05 eq.) was added to a solution of ethyl 2-bromo-4-86168195189 143870-5007-WOfluorobenzoate (3.0 g, 12.1 mmol, 1.00 eq ), (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (3.6 g, 18.5 mmol, 1.20 eq ), and K2CO3 (2.5 g, 18.15 mmol, 1.5 eq.) in dioxane / water (40 ml, V=10:l) at room temperature. The reaction was stirred for 18 hours at 80 °C under N2 and then diluted with water (80 mb). The mixture was extracted with EA (3 x 50 mb). The combined organic layers were washed with brine (2 x 30 mb), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, EA / PE=10 / l) to afford 1.8 g of a white solid (61.8 % yield). MS (ESI+) m / z 239.0 [M+H]+.

[0278] Step 2: Synthesis of (E')-2-(2-ethoxyvinyl)-4-fluorobenzoic acid. NaOH (756 mg, 31.5 mmol, 5.0 eq.) was added to a solution of ethyl (E)-2-(2-ethoxyvinyl)-4-fluorobenzoate (1.5 g, 6.3 mmol, 1.00 eq.) in MeOH / water (25 mb / 5 mb) in one portion. The reaction was stirred for 18 hours at room temperature, concentrated in vacuo, dissolved in water, and acidified to pH 4-5 with HC1 (2 N). The resultant solid was filtered and dried under reduced pressure to give (£)-4-fluoro-2-(2-hydroxyvinyl)benzoic acid (1.1 g, 83 % yield). MS (ESI+) m / z 211.2 [M+H]+. ’ll NMR (400 MHz, DMSO) 5 12.90 (s, 1H), 7.85 (dd, J = 8.8, 6.4 Hz, 1H), 7.42 (dd, J= 11.2, 2.6 Hz, 1H), 7.32 (d, J= 12.8 Hz, 1H), 7.01 (td, J = 8.5, 2.6 Hz, 1H), 6.73 (dd, J= 12.9, 1.4 Hz, 1H), 3.92 (q, J= 7.0 Hz, 2H), 1.27 (t, J= 7.0 Hz, 3H).EXAMPLE 7 - Synthesis of (E)-2-(2-ethoxyvinyl)-6-fluorobenzoic acidStep 1 ep

[0279] Compound (E)-2-(2-ethoxyvinyl)-6-fluorobenzoic acid was prepared via the same method as Example 6.: (270 mg, 76% yield for two steps). MS (ESI+) nEz 211.2 [M+H]+.87168195189 143870-5007-WOEXAMPLE 8 - Synthesis of (E)-2-(2-ethoxyvinyl)-3-fluorobenzoic acid

[0280] Compound (7f)-2-(2-ethoxyvinyl)-3-fluorobenzoic acid was prepared via the same method as Example 6.: (200 mg, 83% yield for two steps) MS (ESI+) m / z 211.2 [M+H]+.EXAMPLE 9 - Synthesis of (E)-2-(2-ethoxyvinyl)-5-fluorobenzoic acid

[0281] The title compound was prepared via the same method as Example 6.: (345 mg, 86% yield for two steps). MS (ESI+) m / z 211.2 [M+H]+.EXAMPLE 10 — Synthesis of N-((l R*,2S*)-2-methoxycyclopropyl)-4-nitrobenzene-sulfonamide and N-((1R *,2S *)-2-hydroxycyclopropyl)-4-nitrobenzenesulfonamideRelative Cis Stereochemistry

[0282] 4-Nitrobenzenesulfonyl chloride (2.37 g, 10.73 mmol, 1.2 eq.) was added to a solution of the mixture of (17?*, 25*)-2-methoxycyclopropan-l -amine hydrochloride and (15*,27?*)-2-aminocyclopropan-l-ol hydrochloride (1.1 g, 8.94 mmol, 1.0 eq.) in pyridine (20 mL) at 0 °C. The reaction was stirred at 0 °C and warmed to room temperature overnight. The mixture was then extracted with EA (3 x 50 mL), washed with brine (2 x 100 mL), dried over anhydrous88168195189 143870-5007-WONajSO,, and concentrated in vacuo. The residue was purified by flash column chromatography eluting with 10% EA in PE to provide A-((17?*,25*)-2-methoxycyclopropyl)-4-nitrobenzenesulfonamide as a yellow solid (220 mg, 9.05% yield). MS (ESI+) m / z 273.2 [M+l]+. Increasing elution to 40% EA in PE provided A-((17?*,2 *)-2-hydroxycyclopropyl)-4-nitrobenzenesulfonamide as a yellow solid (80 mg, 3.45% yield). MS (ESI+) m / z 259.2 [M+l]+.EXAMPLE 11 - Synthesis of (S)-2-(6-fluoro-l-oxoisoquinolin-2(lH)-yl)-N-(4-(N-((lS*,2R*)~ 2-hydroxyclobutyl)su[famoyl)phenyl)-3-(tetrahy(lro-2H-pyran-4-yl)propanami(le (1-21)Relative stereochemistry89168195189 143870-5007-WO0 °C- r.tRelative cis stereochemistry

[0283] Step 1: Synthesis of (5)-2-((tert-butoxycarbonyl)amino)-3-(tetrahydro-2 / / -pyran-4-yl)propanoic acid. To a solution of (5)-2-amino-3 -ftetrahydro-27 / -pyran-4-yl)propanoic acid hydrochloride (1 g, 4.78 mmol, 1.00 eq.) and (BOC)2O (3.3 mL, 14.35 mmol, 3.00 eq.) in H2O (15mL) and dioxane (15 mL) was added TEA (2.1 mL, 14.35 mmol, 3.00 eq.) dropwise at 0 °C under N2. The resulting mixture was stirred for 5 hours at room temperature. The resulting mixture was then adjusted to a pH of 3-4 with citric acid, diluted with water (20 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL). The mixture was concentrated in vacuo to afford (S)-2-(( / erLbutoxycarbonyl)amino)-3-(tetrahydro-22 / -pyran-4-yl)propanoic acid as a colorless oil (1.42 g, 100 % yield). MS (ESI+) m / z 274.2 [M+H]+.

[0284] Step 2: Synthesis of A-((15*,21?*)-2-((tert-butyldiniethylsilyl)oxy)cyclobutyl)-4-nitrobenzenesulfonamide.4-Nitrobenzenesulfonyl chloride (341.5 mg, 1.54 mmol, 1.5 eq.) was added to a solution of (15*,2A*)-2-(( / e / 7-butyldimethylsilyl)oxy)cyclobutan-l-amine (206.9 mg, 1.03 mmol, 1.0 eq.) in pyridine (10 mL) at 0 °C. The reaction was stirred at 0 °C and warmed to room temperature overnight. The mixture was then extracted with EA (3 x 20 mL), washed with brine (2 x 20 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo. The residue was purified by flash column chromatography (25% EA / PE) to provide A-((l> S'*,27?*)-2-((fer / -butyldimethylsilyl)oxy)cyclobutyl)-4-nitrobenzenesulfonamide as a light-yellow oil (249.1 mg, 62.6 % yield).90168195189 143870-5007-WO

[0285] Step 3: Synthesis of tert-butyl 4-amino-A-((l '*,2 / ?*)-2-((tert-butyldimethylsilyl)oxy) cyclobutyl)benzenesulfonamide. Iron (180.0 mg, 3.22 mmol, 5.0 eq.) and NH4CI (344.7 mg, 6.44 mmol, 10.0 eq.), were added to a solution of N-((lS*,2R*)-2-((tert-butyldimethylsilyl)oxy)cyclobutyl)-4-nitrobenzenesulfonamide (249.1 mg, 0.64 mmol, 1.0 eq.) in EtOH / H₂O (10 / 2 mL). The reaction was stirred at 80 °C for 2 hours. The mixture was then filtered and concentrated in vacuo. The residue was extracted with EA (3 x 20 mL), washed with brine (2 x 20 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo to provide 4-amino-Af-((15'*,27?*)-2-(( / er / -butyldimethylsilyl)oxy)cyclobutyl)benzenesulfonamide as a light-yellow oil (232.4 mg, crude). MS (ESI+) m / z 357.2 [M+l]+.

[0286] Step 4: Synthesis of tert-butyl ((. S’)-l-((4-(\-((l. S ',2 / ?‘-)-2-((rert-butyldimethylsilyl)oxy)cyclobutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-2 / / -pyran-4-yl)propan-2-yl)carbamate. Pyridine (0.18 mL, 2.20 mmol, 6.0 eq.) and T3P (698.5 mg, 1.10 mmol, 3.0 eq.) were added to a solution of 4-amino-N-((lS*,2R* 2-((tert-butyldimethylsilyl)oxy)cyclobutyl)benzenesulfonamide (130.5 mg, 0.37 mmol, 1.0 eq.) and S)-2-((tert-butoxycarbonyl)amino)-3-(tetrahydro-27 / -pyran-4-yl)propanoic acid (100.0 mg, 0.37 mmol, 1.0 eq.) in DMF (5 mL) at 0 °C under a N2 atmosphere. The mixture was stirred at 0 °C, warmed to room temperature overnight, extracted with EA (3 x 10 mL), washed with brine (2 x 20 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo. The residue was purified by flash column chromatography (50% EA / PE) to provide ((5)-l-((4-(A-((lS*,2R*)-2-((tert-butyldimethylsilyl)oxy)cyclobutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-27 / -pyran-4-yl)propan-2-yl)carbamate as a light-yellow oil (93.6 mg, 41.8 % yield). MS (ESI+) m z 512.2 [M+l-100]+.

[0287] Step 5: Synthesis of tert-butyl ((5)-l-((4-(A-((1 '*,21?*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-2 / / -pyran-4-yl)propan-2-yl)carbamate. CsF (34.9 mg, 0.23 mmol, 1.5 eq.) was added to a solution of ((5)-l-((4-(A-((15'*,27?*)-2-(( / er / -butyldimethylsilyl)oxy)cyclobutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-2Z / -pyran-4-yl)propan-2-yl)carbamate (93.6 mg, 0.15 mmol, 1.0 eq.) in DMF (5 mL). The reaction was heated at 60 °C under a N2 atmosphere for 3 hours. The mixture was extracted with EA (3 x 10 mL), washed with brine (2 x 20 mL), dried over anhydrous Na2SO4, and concentrated in vacuo to provide ((5)-l-((4-(A-((15’*,2. R*)-2-91168195189 143870-5007-WOhydroxy cy cl obutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-2 / / -pyran-4-yl)propan-2-yl)carbamate as a light-yellow oil (72.9 mg, crude). MS (ESI+) m'z 398.2 [M+l-100]+.

[0288] Step 6: Synthesis of (5)-2-amino-7V-(4-(. V-((lS*,2R*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)-3-(tetrahydro-2H-pyran-4-yl)propanamide hydrochloride. Hydrochloric acid in 1,4-dioxane (1.0 mL) was added dropwise to a solution of ((5)- 1 -((4-(V-(( 15*, 2? *)-2-hydroxycy clobutyl)sulfamoyl)phenyl)amino)- 1 -oxo-3 -(tetrahydro-277-pyran-4-yl)propan-2-yl)carbamate (72.9 mg, 0.15 mmol, 1.0 eq.) inDCM (2 mL) at 0 °C. The reaction was stirred at room temperature for 4 hours and then concentrated in vacuo to provide (5)-2-amino-A-(4-(A-((15*,27? *)-2-hydroxy cyclob utyl)sulfamoyl)phenyl)-3 -(tetrahydro-277-pyran-4-yl)propanamide hydrochloride as a light-yellow solid (57.0 mg, crude). MS (ESI+) m z 398.2 [M+l]+.

[0289] Step 7: Synthesis of 2-((£)-2-ethoxyvinyl)-4-fluoro-A (( )-l-((4-(AL((15'*,27?*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-2 / 7-pyran-4-yl)propan-2-yl)benzamide. DIEA (0.069 mL, 0.39 mmol, 3.0 eq.) was added to a solution of (E)-2-(2-ethoxyvinyl)-4-fluorobenzoic acid (33.1 mg, 0.16 mmol, 1.2 eq.), EDCI (37.8 mg, 0.20 mmol, 1.5 eq.), HOBt (26.6 mg, 0.20 mmol, 1.5 eq.), and DMAP (8.0 mg, 0.066 mmol, 0.5 eq.) in DMF (2 mL) at room temperature under N2. The reaction was stirred at room temperature for 0.5 hour. Then, a solution of ( )-2-amino-A-(4-(A-((1 *,27?*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)-3-(tetrahydro-2 / 7-pyran-4-yl)propanamide hydrochloride (57.0 mg, 0.13 mmol, 1.0 eq.) in DMF (2 mL) was added. The reaction was stirred at room temperature under N2 overnight, extracted with EA (3 x 20 mL), washed with brine (2 x 20 mL), dried over anhydrous Na2SC>4, and concentrated in vacuo. The residue was purified by flash column chromatography (50% EA / PE) to provide 2-((7f)-2-ethoxyvinyl)-4-fluoro-A-((5)-l-((4-(A-((15*,27?*)-2-hydroxycyclobutyl)sulfamoyl) phenyl)amino)-l -oxo-3 -(tetrahydro-277-pyran-4-yl)propan-2-yl)benzamide (21.4 mg, 27.9 % yield). MS (ESI+) m / z 590.2 [M+1]+.

[0290] Step 8: Synthesis of (5)-2-(6-fluoro-l-oxoisoquinolin-2(l / Z)-yl)-A-(4-(Az-((15*,2J?*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)-3-(tetrahydro-2 / 7-pyran-4-yl)propenamide. Hydrochloric acid in 1,4-dioxane (0.02 mL, 0.079 mmol, 2.0 eq.) was added dropwise to a solution of 2-((7y)-2-ethoxyvinyl)-4-fluoro-A-((5)-l-((4-(A-((15*,27?*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)amino)-l-oxo-3-(tetrahydro-277-pyran-4-yl)propan-2-92168195189 143870-5007-WOyl)benzamide (21.4 mg, 0.039 mmol, 1.0 eq.) in DCM (2 mL) at 0 °C. The reaction was concentrated and purified by Prep-HPLC with the following conditions: Column, Xbridge Prep C18 19*250 mm 5pm; Mobile Phase, A: 0.1% Formic acid / H₂O B: ACN; *Gradient: 20% B to 50%B within 15 minutes. UV detection at 254 / 220 nm. The product-containing fractions were combined and concentrated in vacuo and lyophilized overnight to provide (, S')-2-(6-fluoro-l-oxoisoquinolin-2(l / )-yl)-A-(4-(A-((1 *,2A*)-2-hydroxycyclobutyl)sulfamoyl)phenyl)-3-(tetrahydro-2Z / -pyran-4-yl)propanamide as a white solid (3.9 mg, 18.4 % yield). MS (ESI+, m / z): MS (ESI+, m / z): Calcd. for C26H28FN3O6S: Exact Mass: 529.17; found 530.0 [M+H]+; ’H NMR (400 MHz, DMSO) 6 10.78 (s, 1H), 8.28 (dd, J= 8.9, 5.9 Hz, 1H), 7.75 (s, 4H), 7.67 (d, J= 7.6 Hz, 1H), 7.52 (dd, J= 9.8, 2.5 Hz, 1H), 7.39 (d, J= 8.7 Hz, 1H), 7.34 (td, J= 8.8, 2.6 Hz, 1H), 6.71 (d, J= 7.6 Hz, 1H), 5.87 (dd, J= 11.2, 4.9 Hz, 1H), 5.03 (d, J= 4.9 Hz, 1H), 4.11 (d, J= 4.9 Hz, 1H), 3.78 (t, J= 11.4 Hz, 2H), 3.65 (dd, J= 13.2, 6.9 Hz, 1H), 3.17 (dd, J= 11.5, 9.9 Hz, 1H), 3.10 (t, 7 = 10.7 Hz, 1H), 2.22 -2.12 (m, 1H), 2.02 - 1.93 (m, 1H), 1.83 (dt, J= 11.3, 6.5 Hz, 1H), 1.72 (dd, J= 15.3, 7.6 Hz, 2H), 1.59 (dd, J= 14.5, 8.6 Hz, 3H), 1.23 (ddd, J= 16.8, 15.3, 5.5 Hz, 3H). S / R=47.9 / 52.1.EXAMPLE 12 — Synthesis of (S)-2-(6-fluoro-l-oxoisoquinolin-2(lH)-yl)-N-(4-(N-((lR*, 2S*)-2-hydroxycyclopropyl)sulfamoyl)phenyl)-3-(tetrahydro-2H-pyran-4-yl)propenamide (1-18)Relative cis stereochemistry on cyclopropyl

[0291] BBr3(1 N in DCM, 0.368 mL, 0.368 mmol, 5.0 eq.) was added dropwise to a solution of (S)-2-(6-fluoro-l-oxoisoquinolin-2(17 )-yl)-A-(4-( / V-((17?*,25'*)-2-methoxy cyclopropyl) sulfamoyl)phenyl)-3-(tetrahydro-2 / 7-pyran-4-yl)propenamide (synthesized similar to Example 1, 40.0 mg, 0.074 mmol, 1.0 eq.) in DCM (2 mL) at 0 °C. The reaction was stirred at room temperature under N2 for 1.5 hours. The mixture was then quenched with MeOH (ImL), diluted with water (10 mL), extracted with DCM (2 x 10 mL), washed with brine (2 x 10 mL), dried over93168195189 143870-5007-WOanhydrous Na2SO4, and concentrated in vacuo. The residue was purified by Prep-HPLC under the following conditions: Column, Xbridge Prep C18 19*250 mm 5 pm; Mobile Phase, A: 0.1% Formic acid / water B: ACN; ^Gradient: 20% B to 50% B within 15 minutes. UV detection at 254 / 220 nm. The product-containing fractions were combined, concentrated in vacuo, and lyophilized overnight to provide (5)-2-(6-fluoro-l-oxoisoquinolin-2(lJ7)-yl)- / V-(4-( / V-((lA* 2S*)-2-hydroxycyclopropyl)sulfamoyl) phenyl)-3-(tetrahydro-2Z7-pyran-4-yl)propanamide as a white solid (2.7 mg, 6.9 % yield). MS (ESI+, m / z) Calcd. for C27H30FN3O6S: 543.18; found 544.2 [M+H]+. 'H NMR (400 MHz, DMSO) 5 10.82 (s, 1H), 8.29 (dd, J= 8.9, 5.9 Hz, 1H), 7.84 - 7.73 (m, 4H), 7.68 (d, J= 7.6 Hz, 1H), 7.53 (dd, J= 9.8, 2.5 Hz, 1H), 7.42 - 7.28 (m, 2H), 6.71 (d, J = 7.6 Hz, 1H), 5.88 (dd, J= 11.2, 4.9 Hz, 1H), 5.20 (s, 1H), 3.78 (t, J= 10.8 Hz, 2H), 3.14 (dt, J = 26.4, 11.3 Hz, 3H), 2.17 (dd, J= 18.4, 7.1 Hz, 1H), 2.06 - 1.84 (m, 2H), 1.58 (t, J= 11.3 Hz, 2H), 1.36 - 1.17 (m, 3H), 0.63 (q, J= 6.8 Hz, 1H), 0.36 (dd, J= 10.7, 4.5 Hz, 1H).EXAMPLE 13 — Synthesis of Additional Compounds

[0292] The compounds in the following table were prepared based on procedures described above.94168195189 143870-5007-WO95168195189 143870-5007-WO

[0293] Analytical data for exemplary compounds is provide in the table below.96168195189 143870-5007-WOEXAMPLE 14 — USP30 Biochemical IC50 Assay

[0294] Compounds were tested in a USP30 biochemical assay with a dose response to determine the IC50. Experimental procedures and results are provided below.Part I - Experimental Procedures

[0295] A 384-well plate assay using a fluorophore tagged substrate of USP30 was used for in vitro testing of compounds for ability to inhibit USP30. Each test compound was tested at 10 different concentrations (0.5 nM to 10,000 nM) in duplicate wells. Test compounds were preincubated at 25 °C for 30 minutes in an assay buffer consisting of 20 mM Tris / HCl, pH 8.0, 1 mM GSH, 0.01% Triton X-100, 0.03% BGG and 1.5 nM recombinant USP30 (amino acids 57-517 of the human sequence with a C-terminal 6-His tag). Following the pre-incubation, Ubiquitin-Rhodamine substrate dissolved in the assay buffer was added at the final concentration of 25 nM to each well and plates were incubated at 25 °C for an additional 75 minutes. The reaction was stopped by adding 10 mM citric acid, and fluorescence was read using excitation wavelength 485 nm, emission of 535 nm. Data were analyzed using Graph Pad Prism software with a four-parameter (floating slope) fit to log concentration data to determine IC50S.Part II - Results

[0296] Results of the tests are shown in the table below, where +++ indicates an IC50 of less than 0.25 pM, ++ indicates an IC50 in the range of 0.25 pM to 3 pM, and + indicates an IC50 greater than 3 pM. N / A indicates that no data is available.97168195189 143870-5007-WOINCORPORATION BY REFERENCE

[0297] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.EQUIVALENTS

[0298] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.98168195189 143870-5007-WO

Claims

CLAIMS:

1. A compound represented by Formula I:or a pharmaceutically acceptable salt thereof; wherein:R1and R9are independently hydrogen or Ci-4 alkyl;R2is phenyl; a 5-6 membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 4-7 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 4-7 membered deuteroheterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; C1-5 alkyl; C3-7 cycloalkyl; Ci.4haloalkyl; C2-4 alkenyl; C2-C4 allenyl; or C2-4alkynyl; wherein the phenyl, heteroaryl, cycloalkyl, heterocyclyl, deuteroheterocyclyl, C2-4 alkenyl, and C2-4alkynyl are substituted by m occurrences of R4;R3is -S(O)2N(R5)(R6);R4represents independently for each occurrence C1-4 alkyl, Ci.4haloalkyl, halo, C3-7 cycloalkyl, hydroxyl, cyano, or Ci-4alkoxyl;R is hydrogen or Ci-6 alkyl;R6is C1-6 hydroxyalkyl, -(C0-4 alkylene)-(C3-7 cycloalkyl substituted by hydroxyl), -(Co-4 alkylene)-(C3-7 cycloalkyl substituted by -N(R12)(R13)), -(C3-7cycloalkylene)-(Ci-6 hydroxyalkyl), -(Co-4 alkylene)-N(R12)(R13), -(Co-4alkylene)-(3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R11), or -(Co-4alkylene)-(5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R11);R7and R8each represent independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or C3-7 cycloalkyl;R10is C1-6 alkyl, C 1-6 haloalkyl, Ci-ehydroxyalkyl, or C3-7 cycloalkyl;99168195189 143870-5007-WOR11represents independently for each occurrence Ci-4 alkyl, Ci-4haloalkyl, halo, C3-7 cycloalkyl, hydroxyl, or Ci-4alkoxyl;R12and R13are independently hydrogen, Ci-6 alkyl, or C3-7 cycloalkyl;A2is phenylene, pyridinylene, or naphthalenylene, each of which is substituted with q occurrences of R8;L1is -C(O)N(R9)-;X is Ci-5 alkylene;m is 0, 1, 2, or 3; andn, t, and q are independently 0, 1, or 2.

2. The compound of claim 1, wherein the compound is a compound of Formula I.

3. The compound of claim 1 or 2, wherein4. The compound of claim 1 or 2, wherein5. The compound of any one of claims 1-4, wherein R1is hydrogen.

6. The compound of claim 1, wherein the compound is a compound of Formula la, or a pharmaceutically acceptable salt thereof:la7. The compound of claim 1, wherein the compound is a compound of Formula lb, or a pharmaceutically acceptable salt thereof:100168195189 143870-5007-WOIb8. The compound of claim 1, wherein the compound is a compound of Formula Ic-1 or Ic-2, or a pharmaceutically acceptable salt thereof:

9. The compound of claim 1, wherein the compound is a compound of Formula Id, or a pharmaceutically acceptable salt thereof:Id10. The compound of claim 1, wherein the compound is a compound of Formula Ie-1, Ie-2, or If, or a pharmaceutically acceptable salt thereof:Ie-1 Ie-2101168195189 143870-5007-WOIf11. The compound of any one of claims 1-7, wherein n is 1.

12. The compound of any one of claims 1-7, wherein n is 2.

13. The compound of any one of claims 1-12, wherein X is C1.3 alkylene.

14. The compound of any one of claims 1-12, wherein X is -CH2-.

15. The compound of any one of claims 1-14, wherein A2is phenylene substituted with q occurrences of R8.

16. The compound of any one of claims 1-1, wherein R5is hydrogen.

17. The compound of any one of claims 1-16, wherein R6is Ci-6hydroxyalkyl, -(Co-4 alkylene)- (C3-7 cycloalkyl substituted by hydroxyl), or -(C3-7 cycloalkylene)-(Ci-6 hydroxyalkyl).

18. The compound of any one of claims 1-16, wherein R6is -(Co-4alkylene)-(3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R11) or -(C0-4 alkylene)-(5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R11).

19. The compound of any one of claims 1-18, wherein R2is phenyl substituted by m occurrences ofR420. The compound of any one of claims 1-18, wherein R2is a 5-6 membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the heteroaryl and heterocyclyl are substituted by m occurrences of R4.

21. The compound of any one of claims 1-18 wherein R2is C1-3 alkyl or C2-4alkynyl.102168195189 143870-5007-WO22. The compound of any one of claims 1-21, wherein R7is halo.

23. The compound of any one of claims 1-21, wherein R7is fluoro.

24. A compound in Table 1 herein, or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising a compound of any one of claims 1-24 and a pharmaceutically acceptable carrier.

26. A method of treating an USP30-mediated disorder, disease, or condition in a patient, comprising administering to said patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-24.

27. The method of claim 26, wherein the disorder, disease, or condition is selected from the group consisting of a neurodegenerative disease; mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome; Leber’s hereditary optic neuropathy (LHON); neuropathy, ataxia, retinitis pigmentosa- maternally inherited Leigh syndrome (NARP-MILS); Danon disease; ischemic heart disease leading to myocardial infarction; multiple sulfatase deficiency (MSD); mucolipidosis II (ML II); mucolipidosis III (ML III); mucolipidosis IV (ML IV); GM1 -gangliosidosis (GM1); neuronal ceroidlipofuscinoses (NCL1); Alpers disease; Barth syndrome; Beta-oxidation defects; carnitine- acyl-camitine deficiency; carnitine deficiency; creatine deficiency syndromes; coenzyme Q10 deficiency; complex I deficiency; complex II deficiency; complex III deficiency; complex IV deficiency; complex V deficiency; COX deficiency; chronic progressive external ophthalmoplegia syndrome (CPEO); CPT I deficiency; CPT II deficiency; glutaric aciduria type II; Kearns-Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency (LCHAD); Leigh disease or syndrome; lethal infantile cardiomyopathy (LIC); Luft disease; glutaric aciduria type II; medium-chain acyl-CoA dehydrogenase deficiency (MCAD); myoclonic epilepsy and ragged-red fiber (MERRF) syndrome; mitochondrial recessive ataxia syndrome; mitochondrial cytopathy; mitochondrial DNA depletion syndrome; myoneurogastrointestinal disorder and encephalopathy; Pearson syndrome; pyruvate carboxylase deficiency; pyruvate dehydrogenase deficiency; POLG mutations; medium / sh ort-chain 3 -hydroxy acyl-CoA dehydrogenase (M / SCHAD) deficiency; and very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency.103168195189 143870-5007-WO28. The method of claim 26, wherein the disorder, disease, or condition is a neurodegenerative disease selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, ischemia, stroke, dementia with Lewy bodies, and frontotemporal dementia.

29. The method of claim 28, wherein the neurodegenerative disease is Alzheimer’s disease or Parkinson’s disease.

30. The method of claim 26, wherein the disorder, disease, or condition is a neoplastic disease selected from the group consisting of metastatic carcinoma, multiple myeloma, osteosarcoma, chondrosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, and leukemia.

31. The method of claim 26, wherein the disorder, disease, or condition is cardiovascular disease, kidney disease, pulmonary fibrosis, ophthalmic conditions, cancer, cognitive disease, peroxisome related disease, natural aging, or an age-related disease.

32. The method of claim 26, wherein the disorder, disease, or condition is a peroxisome related disease selected from the group consisting of Ataxia-telangiectasia mutated, Heimler syndrome, Infantile refsum disease, Neonatal adrenoleukodystrophy, Rhizomelic chondrodysplasia punctate, White matter dementia, Zellweger syndrome, and Zellweger spectrum disorder.

33. The method of claim 26, wherein the disorder, disease, or condition is glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, acute nephritis, recurrent hematuria, persistent hematuria, chronic nephritis, rapidly progressive nephritis, acute kidney injury, chronic renal failure, diabetic nephropathy, Bartter’s syndrome, chronic kidney disease (CKD), diabetic kidney disease (DKD), Polycystic Kidney Disease (PKD), or igA Nephropathy (igAN).

34. The method of any one of claims 26-33, wherein the subject is a human.

35. A method of inhibiting a USP30 protein, comprising contacting a USP30 protein with an effective amount of a compound of any one of claims 1-24 to thereby inhibit the USP30 protein.104168195189 143870-5007-WO